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Summary 
We aimed at identifying immunodominant Brucella antigens for implementation in new 
detection tools or for subunit vaccine development. In particular, our strategy was to 
produce Brucella cell surface antigen-specific monoclonal antibodies (mAbs) for the 
development of an antigen capture assay for the detection of Brucella cells as potential 
bio threat agents in complex samples. We generated a panel of Brucella 
lipopolysaccharide (LPS)-specific mAbs by immunising mice with inactivated 
B. melitensis and B. abortus cells. The mAbs recognised Brucella species with ‘smooth’ 
LPS independently of the way how the bacterial cells were inactivated. Two mAbs were 
implemented into a bead-based Luminex assay detecting ‘smooth’ Brucella spp. with 
species-dependent detection limits of 2 x 102 to 8 x 104 cells per mL. Integration of the 
Luminex assay into a multiplex format enabled simultaneous detection of Brucella spp. 
and three other bio threat agents within a single sample. The developed Luminex assay 
may be applied for the detection of whole Brucella cells both in natural Brucella 
outbreak and in bioterrorism attack scenarios. 
 
We also tried to generate mAbs against Brucella cell surface proteins from mice 
immunised with inactivated whole Brucella cells. While serum antibody responses 
against both LPS and protein antigens were seen in Western blotting analyses, 
attempts to generate protein-specific mAbs failed, most likely due to the 
immunodominant nature of the LPS. Western blot analyses with Brucella lysate also 
identified antibodies against some immunodominant Brucella proteins in the serum of 
cattle naturally infected with Brucella spp., however, identification of the recognised 
proteins with a Brucella-specific peptide microarray failed. 
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In a second part of the thesis we aimed at evaluating the potential of the 
Plasmodium falciparum reticulocyte-binding homolog 2 (PfRH2) present in the rhoptries 
as a malaria blood stage vaccine antigen. We produced PfRH2-specific mAbs by 
immunising mice with the 40kDa receptor-binding domain of PfRH2. The PfRH2-specific 
mAbs cross-reacted with the natural PfRH2 protein present in schizont stage parasites 
and showed a rhoptry-characteristic staining pattern in immunofluorescence 
microscopy. However when evaluated in functional in vitro and in vivo assays 
PfRH2-specific mAbs showed no inhibitory effect on erythrocyte invasion. Furthermore, 
the invasion-inhibitory effect of mAbs specific for the cysteine-rich protective antigen 
(PfCyRPA) was not enhanced by PfRH2-specific mAbs. 
  
Zusammenfassung ix 
 
 
Zusammenfassung 
Unser Ziel war es immundominante Bruzellen Antigene zu identifizieren, welche in 
neuen Detektionsverfahren oder bei der Impfstoffentwicklung Anwendung finden. Wir 
verfolgten im speziellen die Strategie, spezifische monoklonale Antikörper (mAk) gegen 
Oberflächenantigene von Bruzellen herzustellen und diese für die Entwicklung von 
Antigen Detektionstests zu verwenden um Bruzellen als potenzielle biologische 
Kampfstoffe in komplexen Proben nachzuweisen. Wir produzierten Lipopolysaccharid 
(LPS)-spezifische mAk indem Mäuse mit inaktivierten B. melitensis und B. abortus 
Bakterien immunisiert wurden. Die mAk erkannten Bruzellen Arten mit “glattem“ LPS 
unabhängig davon, wie die Bakterien inaktiviert wurden. Zwei mAk wurden in einem 
Luminex Verfahren, welches auf magnetischen Mikrokugeln basiert, eingesetzt und 
“glatte“ Bruzellen spp. konnten je nach Art bis zu einem spezifischen Detektionslimit von 
2 x 102 bis 8 x 104 Zellen pro mL nachgewiesen werden. Die Umsetzung des Luminex 
Testverfahrens in eine Multiplex Anwendung ermöglichte den gleichzeitigen Nachweis 
von Bruzellen spp. sowie drei weiteren biologischen Kampstoffen in einer einzigen 
Probe. Im Falle eines natürlichen oder bioterroristischen Ausbruchsszenarios, könnte 
das hier entwickelte Luminex Testverfahren für den Nachweis von ganzen Bruzellen 
eingesetzt werden. 
 
Des Weiteren strebten wir an mAk gegen Oberflächenproteine von Bruzellen 
herzustellen indem Mäuse mit inaktivierten ganzen Bruzellen immunisiert wurden. 
Obwohl wir in Western Blot Analysen Serumantikörper Reaktionen gegen LPS und 
Protein Antigene beobachten konnten, war es uns, sehr wahrscheinlich aufgrund der 
Immundominanz des LPS, nicht möglich, Protein-spezifische mAk herzustellen. Ferner 
zeigten Western Blot Analysen auf Bruzellen Lysat, dass Antikörper gegen 
immundominante Bruzellen Proteine im Serum von natürlich infizierten Rindern 
vorhanden sind. Die Bestimmung dieser detektierten Proteine mit Hilfe eines 
Bruzellen-spezifischen Peptid-Mikroarrays war jedoch nicht möglich. 
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Der zweite Teil der Arbeit hatte zum Ziel das "reticulocyte-binding homolog 2“ Protein 
(PfRH2), welches in den Rhoptrien von Plasmodium falciparum zu finden ist, auf seine 
Eignung als potenzielles Vakzin Antigen für Malaria Blutstadien zu untersuchen. 
Nachdem Mäuse mit der rekombinanten 40kDa Rezeptorbindungsdomäne von PfRH2 
immunisiert wurden, konnten PfRH2-spezifische mAk hergestellt werden. Diese 
PfRH2-spezifischen mAk zeigten eine Kreuzreaktivität mit dem endogenen PfRH2 
Protein im Schizontenstadium der Parasiten sowie eine Rhoptrien-charakteristische 
Färbung in der Immunfluoreszenzmikroskopie. Die Evaluierung der PfRH2-spezifischen 
mAk in funktionellen in vitro und in vivo Verfahren zeigte jedoch keine Inhibierung der 
Erythrozyten Invasion. Des Weiteren konnte der wachstumsinhibierende Effekt von 
PfCyRPA- (cysteine-rich protective antigen) spezifischen mAk durch die 
PfRH2-spezifischen mAk nicht gesteigert werden. 
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 Introduction 1.
 Brucellosis 1.1
 Epidemiology 1.1.1
Brucellosis, also known as ‘Malta fever’, ‘undulant fever’ or ‘Bang’s disease’ represents 
the most common bacterial zoonosis worldwide. The disease has been named after 
David Bruce who discovered the genus Brucella in 1887 in a soldier who had died from 
a then unknown febrile illness [1]. Although brucellosis is mainly associated with 
animals, especially domestic livestock, wildlife and marine mammals, it accounts for 
more than 500,000 new human infections annually [2]. Brucellosis shows a worldwide 
distribution and is prevalent in more than sixty countries in almost all continents (Fig. 1) 
with the highest incidences in Central Asia including Mongolia, the Middle East and 
North Africa [3–5]. Recent foodborne outbreaks have been reported from Peru and 
Mongolia threatening thousands of people [6]. 
 
 
Figure 1. Worldwide incidence of human brucellosis since 2000 [4] 
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 Causative organism 1.1.2
The Brucellosis is caused by an infection with gram-negative, aerobe, facultative 
intracellular and non-motile Brucella species (spp.). Genome analyses revealed high 
similarities between almost all members of the Brucella genus. Therefore, there was a 
debate whether B. melitensis could be the ancestor of all other Brucella spp. [2, 7–9]. 
Although, classical virulence genes are absent in Brucella, some factors such as the 
lipopolysaccharide (LPS), the VirB type IV secretion system and flagella genes are 
somehow associated with virulent functions [1, 10]. Upon invasion of the host via the 
respiratory tract, the digestive system or small lesions in the skin, Brucella spp. are 
taken up by phagocytic cells such as macrophages or dendritic cells. Within these cells 
Brucella spp. persist and multiply and can systemically spread within the host body [2]. 
Infections occur in various animals (Table 1) where different Brucella spp. show specific 
host preferences. In shared facilities or pasture however, when different livestock 
species are in close contact transient infections with other Brucella spp. might occur [1, 
2]. The six classical species of Brucella mainly infect domestic animals and rodents 
with, B. melitensis (biovars 1-3) preferentially infecting sheep and goats, B. abortus (1-
6, 9) cattle, B. suis (1, 3) pigs, B. canis dogs, B. ovis sheep and B. neotomae 
preferentially infecting rodents. Yet, some newer species such as B. ceti and 
B. pinnipedialis, B. microti and B. inopinata have been identified also affecting wildlife 
animals including marine mammals [2, 7]. According to new observations from a recent 
study it is hypothesised that amphibians might also be affected by brucellosis since 
potentially novel Brucella spp. were isolated and identified from African bullfrogs [11]. A 
brucellosis infection in animals leads to hygroma formation and abscesses, infertility in 
males but mainly to abortions or still births in pregnant females. Furthermore 
transmission of Brucella spp. between animals occurs via abortions, during mating or 
via bacteria released into the milk. Resulting losses in food-producing animals are of 
great economic importance [2, 12]. 
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Table 1. Host preference of Brucella species [2] 
 
Humans who are accidental hosts for Brucella spp. get infected through direct contact 
e.g. with body fluids or aerosolised Brucella spp. from infected animals, mainly domestic 
livestock but mostly through the consumption of uncooked or unpasteurised animal 
products and through laboratory contacts [1, 9]. Human to human transmission is rare 
which is why humans are suspected to be dead-end hosts [9, 13]. Five Brucella spp., 
B. melitensis, B. abortus, B. suis, B. canis and B. pinnipedialis, are pathogenic for 
humans [3]. However, B. melitensis and B. abortus are the most virulent species in 
humans and responsible for the majority of infections and severe diseases [2, 14]. 
Brucellosis in humans usually presents as an acute febrile illness with flu-like symptoms 
(chills, headache, joint and back pain and weakness) with an incubation time of two to 
four weeks, which can, however, last up to two months and more. The disease can 
cause a systemic infection involving almost any organ or tissue and, may persist for 
weeks or months, especially in the absence of adequate treatment. While human 
infections with brucellosis are rarely fatal (1-2% of cases, mainly due to infective 
endocarditis), persistence, chronification and relapses of the disease cause high 
morbidities [2, 9, 12]. 
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 Diagnosis 1.1.3
Diagnosis of human brucellosis 
Due to the unspecific and variable signs and symptoms of human brucellosis, a clinical 
diagnosis alone is unreliable. Although the clinical history and some background 
information on working activities and eating habits can deliver important clues in the 
anamnesis [12], a suspected brucellosis case should always be confirmed by laboratory 
diagnosis. The gold standard diagnosis for Brucella infections consists of bacteriological 
cultures where the causative agent is isolated and cultivated from blood, bone marrow 
or other tissues and body fluids. Since the bacterial load in the blood is dependent on 
the infection stage, cultures from blood samples are best performed during the 
symptomatic phase of the disease were bacteraemia is highest. Microbiological assays 
may be applied on cultured bacteria to rapidly identify possible Brucella colonies. The 
slide agglutination test is recommended for this purpose using ‘smooth’ Brucella 
antiserum to agglutinate with Brucella spp. from a positive culture. However, since the 
cultivation of Brucella bacteria takes time (approximately from 7 up to 30 days or more), 
is work extensive and hazardous due to the high risk of infection, serological diagnostic 
tests are frequently employed to confirm a first suspicion [15]. Such serological testing 
is fast, non-hazardous, more sensitive and can be applied for routine diagnosis. Yet, 
since all serological assays measure anti-Brucella antibodies, the diagnosis is only 
indirectly linked to an active Brucella infection and diagnosis relies on high or rising 
antibody titres (standard agglutination titres >1:160). Thus, antibodies are present for a 
long time after an acute infection and persisting antibodies due to frequent exposure 
might interfere with the tests and should receive attention. The reference serological 
method is the serum agglutination test (SAT) with a sensitivity of 84.6% to 91.7%. 
However, additional agglutination tests such as the slide, plate or card agglutination are 
also routinely used. The Rose Bengal test (RBT) is a card agglutination test 
recommended by the WHO with a sensitivity of over 99%. In endemic areas the RBT is 
used for rapid screening but the test is prone to cross-reactions with the ‘smooth’ 
lipopolysaccharide (LPS) of other gram-negative bacteria such as 
Yersinia enterocolitica O9, Francisella tularensis, Vibrio cholerae O1 and 
Escherichia coli O157 and positive results need to be confirmed with other more specific 
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methods. Indeed, the ‘smooth’ LPS, the immune dominant antigen of ‘smooth’ 
Brucella spp., is frequently used as the capturing antigen in a variety of standard 
serological assay including RBT, SAT, immunocapture agglutination test (Brucellacapt) 
and enzyme-linked immunosorbent assay (ELISA). Since ‘rough’ Brucella spp. such as 
B. canis and B. ovis do not express a ‘smooth’ LPS, diagnosis with standard serological 
assays are not possible. The Coombs’ test (CT) can be used to complement the SAT 
but is quite complex. The same is true for the complement fixation test (CFT) which is 
not recommended for routine use in small laboratories due to the technical complexity 
but has a high sensitivity of 91.7%. In addition, indirect ELISAs are recommended for 
smaller laboratories and frequently used in routine clinical diagnosis mainly in non-
endemic areas. The sensitivity of the SAT and ELISA are similar in acute cases but the 
ELISA is more sensitive in chronic cases. The Brucellacapt assay showed a high 
sensitivity and specificity of 98% and 96%. SAT, Coombs’ test, CF, ELISA and 
Brucellacapt require proper-equipped laboratories. On the other hand the lateral flow 
assay (LFA) with the principle of a capture ELISA needing only a single drop of blood as 
well as the fluorescent polarisation immunoassay (FPA) where antibodies are bound to 
a fluorescent-labelled Brucella O-polysaccharide antigen, are both rapid point-of-care 
assays suitable for fast and simple testing in poor areas. Sensitivities and specificities of 
these tests are 95% and 95% for the LFA and 96% and 98% for the FPA, respectively 
[12, 14, 15]. 
 
Diagnosis of animal brucellosis 
Testing of livestock is not performed on a regular basis and is rather implemented within 
control and surveillance programs according to country-specific guidelines [1]. For a 
defined diagnosis of animal brucellosis, Brucella spp. have to be cultured and identified 
from infected tissues or organs (e.g. placenta), foetal stomach contents, body fluids or 
milk. The slide agglutination test may be used for a provisional yet fast identification of 
Brucella spp.. Serological assays detecting specific antibodies in serum or milk are 
widely used for practical reasons. The RBT and the buffered plate agglutination test 
(BPAT) are used worldwide for serological diagnosis of Brucella-infected herds. Indirect 
ELISA, CFT and the RBT are recommended for the screening of herds and individual 
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animals. The FPA is highly sensitive (96%) and specific (98%) with human samples but 
evaluations on animals have been limited and need further investigation. The 
milk/Brucella ring test (BRT), which detects IgM and IgA antibodies that agglutinate 
when bound by a pre-stained, inactivated whole B. abortus cell and the indirect ELISA, 
are both used primarily for the detection of antibodies in milk from dairy livestock 
collected from the bulk tank where milk is pooled from different animals. All serological 
assays perform best for the diagnosis of bovine brucellosis (B. abortus) for which they 
are mainly intended. Some modifications are required on these tools in order to test for 
other Brucella spp.. Overall, care has to be taken since antibodies elicited after 
vaccination or infections with other bacteria expressing ‘smooth’ LPS can affect test 
results of serological assays [1, 7, 12]. 
 
Molecular detection tools 
Various PCR-based identification methods have been developed in recent years to 
detect Brucella DNA in cultures or clinical samples including blood, infected tissue or 
organs, body fluids (cerebrospinal and vaginal fluids, semen) and milk of infected 
humans and animals. However, low numbers of bacteria present in some clinical 
samples as well as inhibitory effects from different sample components, interfere with 
the tests. Various sample preparation methods are available commercially for the 
extraction of Brucella DNA and to obtain better purity. Overall, PCR-based assays are 
more sensitive than culture and more specific than serology [15, 16]. Several molecular 
targets are commonly used in conventional and/ or real-time PCR assays to confirm 
Brucella infections including 43kDa, omp2, omp31, 16S rRNA, 16S-23S rRNA spacer, 
bcsp31, IS711, virB2, BMEI1162-IS711 and B. ovis islands. Bcsp31, the gene encoding 
the 31kDa Brucella surface protein, is conserved among all Brucella spp. and used 
most frequently in PCR assays [16]. PCR methods based on a deletion in the eryCD 
operon or mutations in the wboA gene enable the distinction of the vaccine strains 
B. abortus S19 or B. abortus RB51, respectively. The vaccine Rev1 of B. melitensis can 
be detected by PCR methods based on single nucleotide polymorphism (SNP) in the 
rpsL or omp2 gene [16, 17]. In situ hybridisation assays using labelled Brucella DNA or 
the loop-mediated amplification (LAMP) method working at a constant temperature were 
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able to detect Brucella spp. and might be alternative molecular approaches to PCR. 
Furthermore, various molecular approaches identifying Brucella spp. to a species or 
biovar level are available for a differential detection/diagnosis or as epidemiological 
tools [16]. However, molecular assays are not yet routinely implemented in the standard 
laboratory diagnosis of brucellosis [17]. 
 
 Treatment and Prevention 1.1.4
The recommended treatment against brucellosis consists of a combination therapy with 
two antibiotics: doxycycline (200 mg/day) for six weeks together with either 2-3 weeks of 
streptomycin (1 g/day) or with six weeks of rifampicin (600-900 mg/day). Another 
accepted alternative is the combination of 6 weeks of doxycycline (200 mg/day) with 
seven days of gentamicin (5mg/kg/day). Fluoroquinolone or 
trimethoprim/sulfamethoxazole (TMZ/SMZ) antibiotics are likewise used [1, 12]. In case 
of complications such as spondylitis, neurobrucellosis or Brucella endocarditis, longer 
antibiotic therapy, the use of alternative drugs and/or surgery are required. No standard 
treatment has been defined for children below the age of eight years. Overall, an early 
implementation of the treatment using effective drugs as well as an adequate treatment 
length are important to reduce and prevent complications and relapses [12]. Currently, 
no effective and safe vaccine is available for human prophylaxis. However, several 
antigenic proteins have shown a promising protection potential in Brucella mouse 
models [18] and are evaluated for further testing. Brucellosis control and elimination in 
animals is an efficient way to reduce or prevent human infections; but enormous 
financial resources would be necessary to achieve this goal [6, 12]. Therefore, 
education and training on, and provision of, safe food, personal hygiene measures, safe 
working conditions and proper personal and environmental protection are important 
methods supporting vaccinations strategies with life attenuated vaccines (Rev1, S19 
and RB51) to control brucellosis in livestock and prevent human infections [12, 19, 20]. 
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 Potential of Brucella spp. in bioterrorism 1.1.5
The use of biological reagents in warfare can be dated back to the 14th century BC [21]. 
Since then, a vast number of bacteria and viruses have been used for military purposes 
mainly during the First and Second World War [22]. In 1972, the Biological Weapons 
Convention <<on the Prohibition of the Development, Production and Stockpiling of 
Bacteriological (Biological) and Toxin Weapons and on their Destruction>> [23] was 
signed with the consent of international leaders from all over the world. However, 
several attacks for example with Bacillus anthracis (Anthrax) [24] and 
Salmonella typhimurium [25] have been reported after the signing of the convention 
giving rise to fears of bioterrorist attacks by individuals or private organisations. 
Although, there is no evidence that Brucella has ever been used for bioterrorist 
purposes [22], Brucella spp. are classified as category B organisms with the potential 
for application in biological threat situations [26–28]. This classification is explained by 
the facts that Brucella spp. can be easily gained and cultured from natural sources such 
as infected or dead animals, can be efficiently transmitted via aerosols with an 
infectious dose of only ten bacteria, are stable under various conditions and are 
infectious to animals and humans likewise [1, 12]. Although, Brucella spp. are not the 
first choice for a bioterrorism attack, widespread dissemination via the food chain 
through domestic livestock and corn or contaminations during food manufacturing and 
storage possess a major threat to humans especially in areas where brucellosis has 
been eliminated and clinicians, health worker and veterinarians are not aware of the 
disease. Such an altered distribution would affect both the human and animal 
population on a social and economic basis [29–31]. Furthermore, although human 
brucellosis is rarely lethal [32], delayed diagnosis and treatment might lead to severe 
disease with increased mortality [33]. 
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 Malaria 1.2
 Distribution 1.2.1
Malaria, one of ‘the big three’ infectious diseases besides HIV/AIDS and tuberculosis 
[34], affects almost half of the world’s population in 97 countries (Fig. 2). 3.3 billion 
people are at risk for infection with the malaria parasite and for developing the disease. 
Although, a decrease in malaria incidence (30%) and mortality (47%) has been reported 
since 2000, almost 200 million people worldwide are still suffering from malaria with an 
estimated 584’000 deaths in 2013. Countries in sub-Saharan Africa face the highest 
malaria burden accounting for 90% of all malaria deaths of which 87% occur in children 
below the age of five [35, 36]. 
 
 
Figure 2: Countries with on-going transmission of malaria, 2013 [36] 
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 Causative organism 1.2.2
Malaria in humans is caused by five protozoan Plasmodium parasite species, 
P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. P. falciparum is 
responsible for 98% of the malaria-related deaths [37]. Malaria is transmitted to humans 
exclusively via infected female Anopheles mosquito vectors and depends to varying 
degrees also on climate conditions, seasonality and human immunity. Worldwide, 20 
different Anopheles species are important for malaria transmission all of which 
preferentially bite during dusk and night-time [35]. 
 
 P. falciparum life cycle 1.2.3
The life cycle of Plasmodium spp. requires a mosquito vector and the human host to 
undergo repeated asexual and sexual cycles (Fig. 3). During a mosquito bite, infectious 
sporozoites enter the human body and infect hepatocytes where the parasite develops 
into merozoites within 6-15 days. Upon rupture of the infected hepatocytes, merozoites 
enter the bloodstream and actively invade erythrocyte cells through the binding of 
specific receptors at the erythrocyte surface. Within a parasitophorous vacuole, malaria 
parasites undergo distinct development steps, from the so-called ring-stage to the 
trophozoite stage and the schizont stage. On average, 16 merozoites develop asexually 
from each schizont and are released into the bloodstream once the infected erythrocyte 
ruptures. Every merozoite is capable of infecting a new erythrocyte. Each asexual cycle 
of P. falciparum takes 48h and the malaria parasites undergo several such cycles 
before some parasites develop into gendered, sexual gametocytes. These gametocytes 
persist in the blood where they can be taken up by a new mosquito host during a blood 
meal. Within the mosquitos parasites mate and undergo further development steps until, 
after approximately 12 days, infectious sporozoites are formed, able to start a new cycle 
in humans [37–39]. 
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Figure 3: Life cycle of Plasmodium parasites [39] 
 
The asexual stages of P. falciparum are the ones mainly responsible for clinical 
symptoms like fever, headache, chills and nausea which develop approximately 7 days 
after an infectious bite. Depending on the parasite species and immunological status of 
the person, the disease can progress to a critical illness with severe anaemia, general 
shock-like syndrome, lactic acidosis and inflammation of the brain which often results in 
the death of the patient [35, 40]. Young children, pregnant women, individuals with 
HIV/AIDS, travellers and immigrants are at highest risk of developing malaria due to 
insufficient or absent protective immunity [35]. Partial immunity acquired naturally 
through repeated exposure to malaria in highly endemic areas may result in an 
asymptomatic or milder disease and can protect an individual from death. Relapses of 
clinical symptoms are reported for P. vivax and P. ovale infections because the 
parasites latently persist in the liver [35, 40]. 
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 Treatment and Prevention 1.2.4
An early treatment of malaria is important to reduce transmission, severe disease and to 
prevent death. All fever cases with a suspected malaria infection should be confirmed 
with microscopy or rapid diagnostic tests before treatment is applied. To date, 
artemisinin-based combination therapy is the most efficient available treatment, 
especially for malaria caused by P. falciparum [35]. For P. vivax infections, chloroquine 
is the first-line drug of choice which can prevent relapses in combination with 
artemisinin. For areas with reported artemisinin resistance as well as in 
low-transmission areas, a single primaquine dose should be given at day one of the 
artemisinin-based treatment [35, 36]. Another crucial part of malaria control are 
measures to prevent malaria disease and/ or reduce transmission. Important tools to 
this avail are vector control (e.g. indoor spraying of houses with insecticides and 
eliminating potential breeding sites by covering open water around the house), personal 
protection against mosquito bites (insecticide-treated mosquito nets (ITN), protective 
clothing and repellents) and chemoprevention with antimalarial drugs in high 
transmission areas (e.g. for pregnant women and children below 5 years) [35, 36]. 
However, emerging resistance against insecticides and anti-malarial drugs are a major 
concern that weaken frontline malaria control interventions [36]. 
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 Vaccines 1.2.5
To support and maintain malaria control interventions and to follow the Global Malaria 
Action Plan towards elimination and eradication of malaria [41], an efficient vaccine 
against malaria is needed especially in view of emerging insecticide and drug 
resistance. Already in the 1970s vaccination trials with attenuated sporozoites showed a 
protective effect in humans [42, 43]. To date, the RTS,S/AS01 (RTS,S), a 
pre-erythrocytic subunit vaccine targeting the circumsporozoite protein at the surface of 
sporozoites, is the most advanced vaccine candidate. A large phase III trial has been 
completed recently showing that the RTS,S efficiently protects 36% of young children 
(5-17 month) and 26% of infants (6-12 weeks) from clinical malaria in sub-Saharan 
Africa, provided the child received all 4 doses of the vaccine [44, 45]. In October 2015, 
the WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) 
recommended to perform pilot studies to assess whether it is achievable to administer 4 
doses of the RTS,S over the course of 18 months, whether deaths can be prevented 
and whether the vaccine is safe [46–48]. However, as of today, no fully licensed vaccine 
is freely available on the market [35, 41, 44].  
 
Due to the complexity of the parasites life cycle and several potential antigen targets 
present in each parasite stage, vaccine approaches are quite diverse. Pre-erythrocytic 
vaccines aim at preventing infections through sporozoites from an infectious mosquito 
bite or at blood-stage disease by targeting liver stages. This approach requires an 
antibody response against sporozoites or the stimulation of T cells to target intracellular 
hepatocytic stages [49]. The predominant candidate vaccine antigens for this purpose 
are the circumsporozoite protein (CSP [50]) and the thrombospondin-related adhesion 
protein (TRAP [51, 52]). The initial idea for a pre-erythrocytic vaccine evolved when 
mice immunised with irradiated sporozoites showed protection and the same result 
could also be achieved when only the CSP was used for immunisation [53, 54]. 
Additional studies revealed that antibodies against CSP inhibited parasite invasion of 
hepatocytes and reduced the risk of clinical malaria [55, 56]. The CSP is predominantly 
expressed at the surface of sporozoites [57] and is currently the most frequently used 
antigen for different candidate vaccines [58, 59] including the most advanced vaccine 
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RTS,S [44, 45]. TRAP is expressed on the surface of sporozoites and on infected 
hepatocytes [51, 52]. A TRAP-based vaccine achieved a partial protection in 
P. falciparum-naïve adults through the induction of specific IFN-γ producing T cells but 
failed to induce protection in children [60, 61]. However, upon modifications of the viral 
vector the vaccine induced high levels of long-lasting IFN-γ producing T cells [62, 63], 
proved to be safe and immunogenic and has shown to partially protected Kenyan adults 
against P. falciparum infection [64, 65]. A study has recently been conducted to access 
the efficacy of TRAP- and CSP-based vaccines using identical vector systems [66]. 
Further, pre-erythrocytic vaccine antigens in clinical development include the liver stage 
antigens (LSA1 and 3) and the exported protein 1 (Exp-1) [49]. New approaches in the 
clinical development stage use attenuated sporozoites [67–72] which achieved 
protection in more than 90% of volunteers which were immunised with attenuated 
sporozoites through >1000 mosquito bites before challenged [73].  
 
The aim of asexual blood stage vaccines is to eliminate or reduce parasites in the blood 
by preventing merozoite invasion or replication in erythrocytes which is directly affecting 
mortality and morbidity [37, 40]. The rationale behind is that partial protection against 
symptomatic disease and severe malaria in adults can be acquired through natural 
immune responses against blood stage parasite antigens [59]. Few antigens are 
targeted by blood stage vaccines including apical membrane antigen 1 (AMA1 [74–78]), 
erythrocyte-binding antigen-175 (EBA-175 [79]), glutamate-rich protein (GLURP [80–
82]), merozoite surface protein 1 (MSP1 [83]), MSP2 [84, 85], MSP3 [80, 82, 86–89] 
and serine-repeat antigen 5 (SERA5 [90, 91]), all present on the surface of merozoites 
or secreted from apical organelles upon invasion. Naturally acquired immunity against 
all these merozoite antigens have been associated with a certain protection from clinical 
disease [92, 93]. 
Overall, only few blood stage candidate vaccines have been tested in recent years in 
phase II clinical trials to access their protective efficacy in humans. The 
AMA1-combination 1 vaccine adjuvanted with Alhydrogel showed no protective effect 
on clinical malaria or P. falciparum density in young vaccinated children in Mali [78]. In 
malaria naïve adults, receiving a vaccine based on the recombinant AMA1 protein with 
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adjuvant system AS01B or AS02A, no protective effect was seen in challenge 
experiments with P. falciparum-infected mosquitoes but parasitemia was significantly 
reduced in the AMA1/AS02A group [77]. The same vaccine, FMP2.1/AS02A 
(AMA1/AS02A), showed only minor protection (9.9%) against clinical episodes in 
children in Mali within 24 month post vaccination but significantly higher anti-AMA1 
antibody titres [76]. A plasmid DNA vaccine based on AMA1 and CSP in a prime-boost 
regiment with recombinant human serotype 5 adenovirus vectors sterilely protected 
27% of naïve adults when challenged with bites of infected mosquitoes. Protection was 
mainly associated with cell-mediated immunity to AMA1 and CSP [94]. The vaccine 
FMP1/AS02 based on 42-kDa fragment of MSP1 in AS02 induced high anti-MSP1-42 
antibody titres but failed to induce protective efficacy (5.1%) in young Kenyan children 
[83]. A vaccine based on MSP1, MSP2 and the P. falciparum ring-infected erythrocyte 
surface antigen (combination B) in montanide ISA720 reduced parasite density by 62% 
in vaccinated children in Papua New Guinea who were not treated with 
sulfadoxine-pyrimethamine (SP). However, in children receiving SP to clear infections 
prior to vaccination the vaccine had no effect. Furthermore, in both groups no effect on 
clinical malaria episodes were observed [84]. 
 
Transmission-blocking vaccines aim for targeting the sexual gametocyte stages such as 
the surface antigens Pfs48/45 [95–97], Pfs230 [95, 96, 98] and HAP2 [99, 100] or early 
parasite stages within the mosquito such as the 25kDa surface antigen (Pfs25 [101]) by 
preventing the formation of infectious sporozoites to interrupt parasite transmission from 
an infected to an uninfected person [40]. The presence of transmission-blocking 
antibodies in humans from endemic areas drives the idea for such a vaccine [102, 103]. 
Transmission-blocking vaccines do not protect the vaccinated individual from disease 
and therefore need to be used in the entire population to enable overall protective 
coverage employing herd immunity [49]. The leading transmission-blocking candidate 
vaccine is Pfs25 which is the only one tested in human clinical trials so far [104]. A 
vaccine combining the recombinant Pfs25 and Pvs25 of P. falciparum and P. vivax in 
montanide ISA 51 has recently been tested in a phase I trial observing an unexpected 
reactogenic feature and systemic adverse events [101]. 
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Overall, more than 40 pre-clinical and clinical vaccine projects, mainly against 
P. falciparum, evaluate candidate vaccines targeting pre-erythroytic, blood stage and 
sexual stage antigens together with different adjuvants or delivering systems. 
Furthermore, different antigen combinations are included either as stage-specific or as 
multicomponent vaccine [58, 59]. 
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 Hybridoma technology and monoclonal antibodies 1.3
A natural immune response after infection with, or immunisation against, a pathogen, 
stimulates different B lymphocytes (B cell) to produce antibodies. Such a pool of 
antibodies directed against several different epitopes of the antigen is called polyclonal 
and antibodies bind their targets with different specificity and affinity. Next to polyclonal 
antibodies, monoclonal antibodies are identical copies of each other produced by a 
single B cell using the hybridoma technology. Monoclonal antibodies are monospecific, 
binding to only one specific epitope of the antigen [105].  
 
The discovery of the hybridoma technology by Georges J. F. Köhler and César Milstein 
in 1975 revolutionised the wide field of health care and research by providing an 
unlimited supply of specific monoclonal antibodies [106, 107]. In 1984, Köhler, Milstein 
and Niels K. Jerne were awarded the Nobel Prize in Physiology or Medicine <<for 
theories concerning the specificity in development and control of the immune system 
and the discovery of the principle for production of monoclonal antibodies>> [108]. 
Hybridomas are cell hybrids of an antibody-producing B cell with a fast-growing 
cancerous cell which enables the production of large quantities of identical monoclonal 
antibodies. For the production of monoclonal antibodies, mice are immunised with the 
antigen of interest (e.g. whole cells, crude lysate, recombinant proteins or peptides) 
formulated with or without an adjuvant or delivery system (Fig. 4). During the immune 
reaction of the mouse against the antigen, B cells are differentiated in the spleen. 
B cells are antibody-producing cells with a short lifespan of a few days. Repeated 
immunisations are necessary to reach a sufficient antibody titre and to generate 
high-affinity antibodies [109, 110]. 
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Figure 4: Production of monoclonal antibodies [109] 
 
A hybridoma is then produced by fusing a splenocyte-derived B cell to a cancerous 
myeloma cell in the presence of polyethylene glycol (PEG) which mediates the fusion 
process by permeableising the cell membranes. Myeloma cells (e.g. P3X63-Ag8, NS1, 
SP2/0 [109]) are immortal. Furthermore, they lack the enzyme hypoxanthine guanidine 
phosphoribosyltransferase (HGPRT) and are thus sensitive to the enzyme inhibitor 
aminopterin which blocks the de novo synthesis of nucleotides. Normal cells have two 
different pathways for the biosynthesis of nucleotides, the de novo pathway and the 
salvage pathway. For the salvage pathway, the HGPRT enzyme must be present to 
synthesise nucleotides. Cells which are lacking HGPRT, such as myeloma cells, are 
thus killed in the presence of aminopterin. This feature is exploited to select suitable 
hybridomas. Hybridised cells are grown in a hypoxanthine-aminopterin-thymidine (HAT) 
selective medium with splenocyte-myeloma hybrids being the only surviving and 
growing cells. This stems from the fact that correctly fused hybridomas survive in the 
presence of aminopterin due to the ability for eternal life (coming from the myeloma cell) 
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and the presence of the HGPRT enzyme enabling salvage-dependent DNA synthesis 
(coming from the splenocyte counterpart). Incorrectly fused splenocyte-splenocyte 
hybrids are inherently short-lived and die fast whereas myeloma-myeloma hybrids die 
because they cannot use the salvage pathway for DNA synthesis due to the 
HGPRT-deficiency and the fact that the de novo pathway is blocked by aminopterin 
presence in the HAT medium.  
Culture supernatant has to be tested for the presence of antibodies secreted by 
hybridoma cells. Therefore an appropriate screening assay has to be defined and 
special care is required regarding the antigen used in the assay to avoid selection of 
unspecific antibodies. Selected hybridoma lines are cloned by limiting dilutions to 
ensure monoclonal growth. Before expanding a certain hybridoma line for large-scale 
production of antibodies, the antibody isotype is determined. This is crucial to select 
which antibody purification technique is appropriate and also serves as control to 
guarantee monoclonal growth. After antibody purification, further characterisation steps 
are required such as specificity testing, epitope mapping and affinity measurements 
according to the field of application [109, 110]. 
 
For the use in scientific or therapeutic purposes, poly or monoclonal antibodies are 
selected primarily according to the intended use. However, other factors concerning the 
production and purpose can influence the decision. For the production of polyclonal 
antibodies rabbits, sheep, goats and chicken are used with the goal to obtain high 
quantities of antibodies. The production is fast, inexpensive and quite easy to perform. 
The heterogeneity of polyclonal antibodies in the binding of different antigen epitopes is 
the reason for their high overall specificity and renders polyclonal antibodies more 
stable against antigenic changes. However, the supply of polyclonal antibodies is limited 
by the production capacity of immunised animals (depending on size and lifespan) and 
antibodies obtained from different animals are slightly diverse due to individual immune 
responses [105, 110]. Monoclonal antibodies are completely homogeneous which 
enables different epitope-specific evaluations and characterisations of target molecules. 
Due to their monospecificity, monoclonal antibody-based assays may be susceptible to 
epitope alterations which affect the antibody binding site. Several monoclonal antibodies 
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with different defined specificities can be combined in one assay to overcome this 
problematic. Although the selection of appropriate B cells and the production of 
monoclonal antibodies using the hybridoma technology is time consuming, expensive 
and requires trained personnel, once a hybridoma is generated, the supply of identical, 
highly pure and epitope-specific monoclonal antibodies is consistent and unlimited 
[105]. 
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 Goals and Objectives 2.
 Goals 2.1
The goals of the thesis were:  
i. to identify immunodominant antigens of Brucella spp. and to generate 
specific monoclonal antibodies against them for implementation in new 
detection tools for Brucella cells or for subunit vaccine development  
ii. to evaluate the potential of PfRH2 as a P. falciparum malaria blood stage 
vaccine candidate antigen 
 
 
 Objectives 2.2
1. To identify immunodominant Brucella antigens by analysing sera from mice 
immunised with whole Brucella cells and cattle naturally infected with Brucella spp. 
2. To generate monoclonal antibodies against Brucella cell surface antigens with 
spleen cells of mice immunised with whole Brucella cells or with recombinant 
Brucella proteins 
3. To develop an antigen capture assay for the detection of Brucella bacteria 
4. To establish a multiplex assay for the simultaneous detection of Brucella spp., 
Bacillus anthracis, Francisella tularensis and Yersinia pestis in complex samples 
5. To generate Plasmodium falciparum reticulocyte-binding homolog 2 
(PfRH2)-specific monoclonal antibodies from mice immunised with the 40kDa 
receptor-binding domain of PfRH2 
6. To evaluate the potential of PfRH2-specific monoclonal antibodies to inhibit 
erythrocyte invasion by P. falciparum merozoites in vitro and in vivo 
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 Abstract 3.1
Background 
Brucella, a Gram-negative bacterium, is classified as a potential bioterrorism agent 
mainly due to the low dose needed to cause infection and the ability to transmit the 
bacteria via aerosols. Goats/ sheep, cattle, pigs, dogs, sheep and rodents are infected 
by B. melitensis, B. abortus, B. suis, B. canis, B. ovis and B. neotomae, respectively, 
the six classical Brucella species. Most human cases are caused by B. melitensis and 
B. abortus. Our aim was to specifically detect Brucellae with ‘smooth’ lipopolysaccharide 
(LPS) using a highly sensitive monoclonal antibody (mAb) based immunological assay. 
 
Methods 
To complement molecular detection systems for potential bioterror agents, as required 
by international biodefense regulations, sets of mAbs were generated by B cell 
hybridoma technology and used to develop immunological assays. The combination of 
mAbs most suitable for an antigen capture assay format was identified and an 
immunoassay using the Luminex xMAP technology was developed. 
 
Results 
MAbs specific for the LPS O-antigen of Brucella spp. were generated by immunising 
mice with inactivated B. melitensis or B. abortus cells. Most mAbs recognised both 
B. melitensis and B. abortus and antigen binding was not impeded by inactivation of the 
bacterial cells by γ irradiation, formalin or heat treatment, a step required to analyse the 
samples immunologically under biosafety level two conditions. The Luminex assay 
recognised all tested Brucella species with ‘smooth’ LPS with detection limits of 2 x 102 
to 8 x 104 cells per mL, depending on the species tested. Milk samples spiked with 
Brucella spp. cells were identified successfully using the Luminex assay. In addition, the 
bead-based immunoassay was integrated into a multiplex format, allowing for 
simultaneous, rapid and specific detection of Brucella spp., Bacillus anthracis, 
Francisella tularensis and Yersinia pestis within a single sample.  
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Conclusion 
Overall, the robust Luminex assay should allow detection of Brucella spp. in both 
natural outbreak and bio threat situations.  
 
 
 
 
 
Keywords 
Brucellosis, Luminex, antigen capture assay, monoclonal antibodies, multiplex 
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 Introduction 3.2
Brucellosis, a zoonotic bacterial disease caused by Gram-negative Brucellae and 
classified as a potential bioterrorism disease [1], leads to abortions in animals and 
flu-like symptoms with periodic bouts of fever in humans. B. melitensis, B. abortus, 
B. suis, B. canis, B. ovis and B. neotomae are the six classical species that infect mainly 
goats/ sheep, cattle, pigs, dogs, sheep and rodents, respectively, while B. melitensis 
and B. abortus cause most of the human infections [2–4]. Like other Gram-negative 
bacteria, Brucellae express lipopolysaccharide (LPS), a major component of the outer 
membrane. The three structural components of LPS are the lipid A, the core 
oligosaccharide and the O-polysaccharide (O-antigen). In ‘smooth’ Brucella species, the 
O-polysaccharide is a linear polymer of 4,6-dideoxy-4-formamido-α-D-mannopyranosyl 
residues, whereas ‘rough’ strains have a truncated version without the O-antigen [5, 6]. 
Brucella LPS is able to induce protective antibodies [7–9], which are potentially 
important for serological diagnosis [10–16]. Because of the threat posed by natural 
outbreaks or by a deliberate release of the bacteria as a bioterror agent [17], there is a 
need for rapid and reliable identification systems, preferably based on multiplex formats 
covering a range of relevant species. This is especially important for fastidious agents 
such as Brucella or Francisella species where tracing by cultivation is hampered by long 
cultivation time.  
 
The aim of this study was to develop a rapid and sensitive immunological assay to 
detect all Brucellae with ‘smooth’ LPS, particularly B. melitensis and B. abortus. To this 
end, monoclonal antibodies (mAbs) specific for Brucella LPS were generated and used 
to design a highly specific and sensitive antigen capture assay. An optimal combination 
of mAbs was identified and a Brucella LPS-specific Luminex xMAP assay [18, 19] was 
developed, capable of detecting four of the major Brucella species (B. melitensis, 
B. abortus, B. suis, B. neotomae) with high sensitivity. Additionally, the Luminex assay 
works in a multiplex format, simultaneously detecting four category A and B bacterial 
bioterrorism agents and suitable for detecting Brucella in complex samples. 
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 Materials and Methods 3.3
Ethics Statement 
This study was carried out in strict accordance with the Rules and Regulations for the 
Protection of Animal Rights (Tierschutzverordnung) of the Swiss Federal Food Safety 
and Veterinary Office. The protocol was granted ethical approval by the Veterinary 
Office of the county of Basel-Stadt, Switzerland (Permit Number: 2375). 
 
Production and inactivation of bacteria 
Bacterial strains used in this study are listed in Table 1. Brucella spp. were cultured on 
Columbia blood agar plates supplemented with 5% goat blood [20]. Bacteria were 
inactivated by 3% formalin (55 °C for 15 min), heat (60 °C for >20 h) or gamma (γ) 
irradiation at 30-40 kGy (Leoni Studer Hard AG, Däniken, Switzerland). Sterility was 
checked by incubating bacteria for three days on agar plates and no growth was 
observed.  
 
Production of anti-LPS mAbs 
To produce Brucella LPS-specific mAbs, mice carrying human immunoglobulin Cγ1 
heavy and Cκ light chain gene segments [21] were immunised four times 
subcutaneously with a dose of 108 CFU of differentially inactivated Brucella species, 
either adjuvant-free or as adjuvanted formulation, in combination with the Sigma 
Adjuvant System® (SAS, Sigma Aldrich). Mice received either gamma (γ) irradiated 
B. melitensis in sterile Phosphate buffered saline (PBS, Sigma Aldrich), γ irradiated 
B. melitensis with SAS, formalin inactivated B. melitensis in PBS or formalin inactivated 
B. abortus in PBS.  
Three days before cell fusion, two selected mice received an intravenous booster 
injection with 108 Brucella cells in PBS. Myeloma cells (PAI) were mixed 1:3 (fusion 1) 
and 1:1 (fusion 2) with spleen cells from the corresponding mouse in Iscove’s Modified 
Dulbecco’s Medium (IMDM, Sigma Aldrich). Cells were fused with 1 mL of pre-warmed 
(37 °C) Polyethylene glycol (PEG 800, Roche), dissolved in 150 mL HAT selective 
medium (IMDM 1% 200 mM L-Glutamine (100X), 1% Pen/Strep (100X, 
[+] 10,000 Units/mL Penicillin [+] 10,000 µg/mL Streptomycin, Gibco), 20% FBS, HAT 
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media supplement 50X Hybri-Max™, Sigma Aldrich) and cultured in 96-well tissue 
culture plates. Cells secreting Brucella-specific IgG were identified by ELISA coated 
with γ irradiated B. melitensis cells (16 M). From the two independent fusions, eleven 
hybridoma cell lines producing LPS-specific mAbs were identified and cloned by limiting 
dilution. MAbs were purified from spent culture supernatant of the hybridoma clones by 
protein A affinity chromatography (HiTrap rProtein A FF, Amersham Biosciences). 
Purified mAbs were dialysed against PBS, aliquoted, and stored at -80 °C. 
 
Enzyme-linked immunosorbent assay (ELISA) 
In indirect ELISA (iELISA), Maxisorp™ microtitre plates (Nunc, Thermo Scientific) were 
coated for 36 hours at 4 °C with 50 µL of a 10 µg/mL solution of extracted LPS or with 
50 µL of a bacterial suspension containing 107 inactivated Brucella cells per mL. Wells 
were then blocked with 5% milk powder in PBS for two hours, followed by three 
washings with PBS containing 0.25% Tween-20. Plates were incubated with appropriate 
dilutions of mouse sera or anti-LPS mAbs in PBS for 1-2 hours at room temperature. 
After washing, plates were incubated with horseradish peroxidase-conjugated goat anti-
mouse IgG (γ-chain specific) antibodies (Southern Biotech) for one hour. TMB (TMB 
Microwell Peroxidase Substrate System (2-C), KPL) or ABTS substrate (ABTS® 
Peroxidase Substrate System, KPL) was added and incubated at room temperature 
until appropriate colour intensity was reached (five to 30 min). The optical density (OD) 
of the reaction product was recorded after five to 30 minutes at 570 nm or 405 nm using 
a microplate reader. 
In antigen capture ELISA (cELISA), microtitre plates were coated with 50 µL of a 
10 µg/mL solution of unlabelled mAbs in PBS. After being blocked and washed, wells 
were incubated with dilutions of inactivated Brucella cells in PBS. Biotinylated detection 
mAbs (10 µg/mL) were added and incubated for one hour. After repeated washing, 
streptavidin-peroxidase polymer conjugate (1 µg/mL, Sigma Aldrich) was added and 
developed with the ABTS substrate. 
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Isotypes of anti-LPS mAbs were determined by detecting mAbs bound to anti-mouse 
lambda light chain antibody-coated plates with alkaline phosphatase-conjugated 
antibodies specific for mouse IgG1, IgG2a, IgG2b or IgG3 (Southern Biotech). 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting 
Aliquots of extracted LPS from B. melitensis and B. abortus were mixed with sample 
buffer (Laemmli buffer, Invitrogen) and heated for 15 min at 96 °C before loading on 
4-12% Bis-Tris gels. SeeBlue® pre-stained protein standard (Invitrogen) was used as a 
molecular weight marker. Following gel electrophoresis, LPS was transferred 
electrophoretically to nitrocellulose membranes. Blots were blocked for two hours with 
5% milk powder in PBS, cut into strips and then incubated with purified mAbs 
(10 µg/mL) for one hour. The strips were washed four times for 15 minutes with PBS 
containing 0.05% Tween-20 and incubated with alkaline phosphatase-conjugated goat 
anti-mouse IgG heavy-chain antibodies (Sigma Aldrich) for one hour. Strips were 
treated with 5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium to visualise 
bands. 
 
Immunofluorescence assay (IFA)  
30 µL droplets of a fixing solution containing 4% paraformaldehyde and 10% PBS were 
placed in each well of a pre-coated Poly-L-Lysin microscope glass slide (Diagnostic 
Microscope Slides ES-242B-AD-CE24, Thermo Scientific). Ten µL of a bacterial 
suspension containing 108 γ irradiated B. melitensis (16 M) or B. abortus (544) cells 
were added to each well and incubated for 30 min at room temperature. Wells were 
washed five times with PBS and then incubated for 15 min with 50 µL of blocking buffer 
containing 1% fatty acid-free bovine serum albumin (BSA) in PBS. Afterwards, 30 µL of 
10 µg/mL mAbs diluted in blocking buffer were added and incubated for one hour. Wells 
were washed five times with blocking buffer before 30 µL of detection antibody (Alexa 
Fluor 568 (2 mg/mL, Invitrogen) conjugated donkey anti-mouse IgG (H+L), 1:400 in 
blocking buffer) was added for an additional hour. Finally, wells were washed five times, 
mounted with ProLong® Gold antifade reagent with 4',6-diamidino-2-phenylindole 
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(DAPI, Invitrogen) and covered with a coverslip. Antibody binding and DNA staining 
were assessed by fluorescence microscopy. 
 
Luminex assay 
Anti-LPS mAbs were coupled to magnetic beads (Bio-Plex Pro Magnetic COOH Beads, 
Biorad) according to the manufacturer's instructions and adjusted to a working 
concentration of 40 beads/µL in blocking buffer (1% BSA in PBS). In the coupling 
reaction, 6 µg of antibody was applied to 5 × 105 beads. Fifty µL of working bead 
mixture was used per microtitre well. Fifty µL bacterial samples were then added to 
each bead-containing well and incubated for two hours on a microplate shaker at 37 °C 
in the dark. After incubation, the plates were washed with PBS containing 0.05% 
Tween-20 and the beads were resuspended in 50 µL of biotinylated detection antibody 
at a concentration of 10 µg/mL in blocking buffer and incubated for 1 hour. After 
repeated washing, 50 µL of a streptavidin-R phycoerythrin (ProZyme Inc.) solution was 
added and incubated for 30 min. The plate was then washed and the beads 
resuspended in 125 µL of blocking buffer before loading onto the BioPlex 200 
instrument (Bio-Rad Laboratories). Reporter fluorescence was measured and 
expressed as mean fluorescence intensity of at least 100 beads per region. Multiplexed 
assays were performed in a single well format with mAb pairs 3D12/10G1 (Brucellae), 
MTA1/MTD6 [19], YPF19/YPF19 [22] and T14/FB11 [23]. 
 
Statistical analysis 
All data were obtained from experiments performed in duplicate (at a minimum). 
Antigen-free controls consisted of PBS (instead of sample suspended in PBS) and were 
further diluted with the diluent used for the particular assay. These controls were 
included in each experiment to determine the cut-off. Mean value, standard deviation 
and LOD (limit of detection) were calculated in Excel. Figure assembly, data 
transformation and non-linear regression (sigmoidal curve, dose-response variable 
slope) were done with GraphPad Prism.  
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 Results 3.4
Generation and characterisation of Brucella LPS-specific mAbs  
Two mice exhibiting high ELISA IgG titres against B. melitensis (16 M) or B. abortus 
(NCTC 10093 544) cells after immunisation with inactivated bacterial cells were chosen 
for the generation of Brucella LPS-specific mAbs. Eleven hybridoma cell clones were 
obtained by screening with a B. melitensis (16 M, γ irradiated, 5 x 107 CFU/mL) whole 
cell ELISA. Two mAbs (3A10 and 4F11) were generated from a mouse immunised with 
γ irradiated B. melitensis, and nine (1A3, 10G1, 3D12, 2G12, 2G2, 1B6, 2E3, 5B10, 
1E2) from a mouse immunised with formalin inactivated B. abortus cells. Determination 
of the mouse IgG subclass of the produced LPS-specific mAbs showed a predominance 
of the IgG2b(λ) isotype; only mAbs 4F11 and 1E2 were of the IgG3(λ) isotype. While all 
11 mAbs recognised extracted LPS from B. abortus (type A O-antigen), mAbs 1E2 and 
4F11 showed a markedly weaker reactivity with B. melitensis LPS (type M O-antigen) 
than did the others in ELISA (Fig. 1A) and Western blotting (Fig. 1C). The Western blot 
profiles (Fig. 1C) were typical for ‘smooth’ LPS of Brucella spp. [24]. In 
immunofluorescence analysis with inactivated B. melitensis and B. abortus cells, all 
anti-LPS mAbs yielded a homogenous circular surface staining. Figure 1B shows a 
representative staining for mAbs 3D12 and 10G1 with B. melitensis cells. The 
differences in the fine-specificities of the mAbs observed in ELISA correlated with 
differences in immunofluorescence analysis, where surface staining by mAbs 1E2 and 
4F11 with B. melitensis cells was weak (data not shown). For the analysis of the 
samples under biosafety level two conditions, inactivation is required. Different 
methods, γ irradiation, formalin inactivation and heat treatment, are available for that. 
Irrespective of the inactivation method, the anti-LPS mAbs reacted with B. melitensis 
and B. abortus cells in ELISA (Fig. 1D).  
 
To develop a highly sensitive antigen capture assay, a suitable combination of a 
capturing and a biotinylated-detecting mAb was selected from the pool of 11 mAbs. In a 
sandwich ELISA format, the majority of mAb combinations tested were suitable for 
detecting B. melitensis cells (Fig. 2). Despite its weak reactivity with B. melitensis LPS, 
mAb 1E2 could effectively be used as a capture antibody but it failed to interact with 
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B. melitensis cells when used as a detection antibody. A differentiation between 
B. melitensis and B. abortus cells was thus only observed with mAb 1E2 as a detection 
antibody (data not shown). MAb 3D12 performed best as an antigen capture antibody 
while mAb 10G1 was selected as the detection antibody as it gave the highest read out 
in combination with mAb 3D12 as the capture antibody. Hence, further development 
focussed on the mAb pair 3D12/10G1. 
 
Developing a Luminex assay for rapid and sensitive detection of Brucella spp. 
The mAb pair 3D12/10G1 was used to develop an antigen capture assay based on 
Luminex xMAP technology. While similar to ELISA in overall assay format, the Luminex 
technology combines advanced fluidics, optics, and digital signal processing with up to 
500 color-coded microspheres to provide an accurate measurement of multiple analytes 
from a single sample [25]. Each bead set can be conjugated to a specific biomolecule 
(such as an antibody) to capture analytes of interest using a very small sample volume. 
Here, the mAb 3D12 was coupled to magnetic beads and used as the capture antibody, 
and the biotinylated mAb 10G1 was used as the detection antibody. The sensitivity of 
this Luminex assay was determined by analysing serial dilutions of inactivated 
B. melitensis, B. abortus and B. suis cells. The limit of detection (LOD) was calculated 
as the mean fluorescence intensity of the blank plus three times the standard deviation 
(SD) and set as the threshold (dashed line in Fig. 3A). The detection limits in a sample 
volume of 50 µL were 2 x 102 cells per mL for B. melitensis, 5 x 103 cells per mL for 
B. abortus and 8 x 104 cells per mL for B. suis. Depending on the species tested, the 
sensitivity of the Luminex assay was 4 to 50 times higher than that of a corresponding 
antigen capture ELISA (Fig. 3B), where at least 104, 2 x 104 and 3 x 106 cells per mL, 
respectively, were required for accurate detection.  
 
The specificity of the bead-based assay was tested with several biotypes of 
B. melitensis (1-3), B. abortus (1,3), B. suis (1,2), B. canis, B. ovis and B. neotomae, as 
well as with other potential bioterror agents (F. tularensis, B. anthracis, S. typhimurium, 
Y. pestis, B. mallei, B. pseudomallei [1]) and bacteria (Y. enterocolitica O9, E. coli O157 
and V. cholera O1 [26–29]) with structurally similar O-antigens of α1,2-linked 4-amino-
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4,6-dideoxy-α-D-mannopyranosyl subunits and O. anthropi, the closest relative of 
Brucellae [30]. The Luminex assay detected all ‘smooth’ Brucella species (B. melitensis, 
B. abortus, B. suis and B. neotomae) independently of their biotype (Table 2). Overall, 
Brucella species expressing the M O-antigen were detected with higher sensitivity 
compared to A or AM O-antigen expressing Brucella. Cross-reactivity with 
Y. enterocolitica O9 was found, as predicted by the structural identity of the type A 
O-antigen [27, 28]. Neither B. canis nor B. ovis cells expressing a ‘rough’ LPS nor any 
of the other bacterial species tested gave positive signals. 
 
The newly developed singleplex assay for Brucella spp. was integrated into a previously 
established multiplex assay to allow for simultaneous detection of the four potential 
bioterror agents, B. melitensis, B. anthracis, F. tularensis and Y. pestis, in a single run 
of the assay. Mixed samples containing combinations of the four bacterial species were 
prepared in PBS and tested in the multiplexed immunoassay format (Fig. 4A). All four 
bio threat agents tested were accurately detected and no cross-reactivities between 
individual singleplex assays were observed. The specificity of the Luminex assay for 
B. anthracis, F. tularensis and Y. pestis had been tested prior to the multiplex testing 
(Additional file 1 and 2). 
 
In addition, the multiplex assay specifically identified all four bacterial species from a 
spiked milk sample, indicating that the newly developed Luminex assay is also suitable 
for detecting Brucella spp. in complex biological samples (Fig. 4B). 
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 Discussion 3.5
Brucellosis is one of the most common bacterial zoonosis worldwide and an important 
cause of economic losses and human suffering [2, 4]. Moreover, B. abortus, 
B. melitensis and B. suis could be developed as bioterrorism agents due to their ability 
to undergo aerosolisation [31]. Isolation by cultivation is the standard method for 
identifying Brucella bacteria in biological samples, but may take up to four weeks to 
complete. Methods based on the polymerase chain reaction that identifies nucleic acid 
fragments from bacteria are becoming more practical for detecting Brucella spp. [32, 
33]. However, according to international biodefense regulations, immunological 
detection methods for potential bioterror agents are required in addition to molecular 
detection and identification assays.  
 
In this study, we showed that Brucella O-antigen-specifc mAbs represent potent 
immuno-capturing components for a highly sensitive detection system for Brucella cells 
in complex samples. Immunisation of laboratory mice with inactivated Brucella bacteria 
combined with a B. melitensis whole cell ELISA for selecting B cell hybridoma lines that 
produce Brucella-specific antibodies yielded exclusively LPS-specific mAbs, although 
anti-protein IgG antibodies could also be detected in the serum of the immunised mice 
(data not shown). This observation might be explained by the fact that in ‘smooth’ 
Brucella species, outer membrane proteins and other membrane components are 
masked by O-polysaccharide chains of LPS [34, 35]. All of the mAbs generated 
recognised LPS from B. abortus (type A O-antigen) and from B. melitensis (type M 
O-antigen). However, mAbs 1E2 and 4F11 differed from the other mAbs in 
fine-specificity in that they showed a markedly reduced reactivity with B. melitensis LPS. 
None of the sample inactivation methods tested (γ irradiation, formalin and heat 
treatment) affected the interaction between the mAbs produced and the bacterial cells, 
corroborating the suitability of Brucella LPS as a stable target antigen for detection. 
Dependent on infrastructural constraints (i.e. availability of gamma irradiation) and 
application, laboratories may have different preferences concerning the inactivation 
method.  
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As expected from the comparative binding studies, the majority of the mAb 
combinations tested were suitable for detecting Brucella cells in a sandwich capture 
ELISA format. A differentiation between B. melitensis and other Brucella species 
expressing ‘smooth’ LPS was achieved with mAb 1E2 in a suitable test format. The 
Luminex immunoassay with the selected mAb pair, 3D12 and 10G1, captured and 
detected cells of all ‘smooth’ Brucella species and biotypes tested but also showed 
cross-reactivity with Y. enterocolitica serotype O9. The O-antigens of Y. enterocolitica 
O9, E. coli O157, V. cholera O1 and B. abortus all consist of a linear polymer of 
α1,2-linked 4-amino-4,6-dideoxy-α-D-mannopyranosyl residues (perosamine). 
However, they differ in the N-acylation of the perosamine sugar [26]. While B. abortus 
and Y. enterocolitica O9 are N-acylated with formic acid, V. cholera O1 are substituted 
with (S)-2,4-dihydroxybutanoic acid [36]. These derivatisations can have major effects 
on antibody binding, which may explain why our mAbs only showed cross-reactivity with 
Y. enterocolitica O9. PCR can verify whether a result obtained with mAb pair 
3D12/10D1 is true or false positive due to Y. enterocolitica O9 contamination. To 
conclusively analyse environmental samples a combination of molecular and 
immunological methods is recommended [37]. Our mAbs are specific to Brucella 
carrying ‘smooth’ LPS, hence a detection of ‘rough’ Brucella species is not possible. A 
LPS-independent detection based on surface-exposed structures might solve this 
problem.  
 
Depending on the Brucella species tested, the assay was able to detect 10 to 4,000 
cells in a sample volume of 50 µL. Currently available molecular identification assays for 
Brucella spp. offer comparable or even lower detection limits [32, 33, 38]. 
Recently, a capture ELISA for diagnostic purposes was developed using LPS-specific 
monoclonal antibodies to detect LPS antigens in the blood [39]. Both, our approach for 
generating LPS-specific monoclonal antibodies, as well as the overall purpose of our 
test development were different. We developed a highly sensitive Luminex multiplex 
assay for the detection of bio threat agents both in natural outbreak and bio threat 
situations. 
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The conversion of the ELISA into the Luminex bead-based assay markedly increased 
the sensitivity for detecting Brucella and allowed integration of the Brucella assay into a 
multiplex assay to simultaneously detect a range of relevant bio-threat species. The 
multiplexed immunodetection assay accurately detected Brucella spp., B. anthracis, 
F. tularensis and Y. pestis cells within a single mixed sample. Brucellosis is transmitted 
to humans through consumption of unpasteurised dairy products or through direct 
contact with infected animals. Although detecting Brucella cells in milk is complicated 
[40], the Luminex multiplex assay specifically identified all tested bacterial species from 
spiked milk samples, demonstrating that the developed assay is a suitable tool for 
detecting Brucella cells in complex samples.  
 
 
 Conclusion 3.6
The Luminex assay described here is a suitable tool for specifically detecting 
Brucella spp. even in complex samples such as milk. Four bio-threat agents can be 
detected in the multiplex format, quickly and specifically. Overall, using the Luminex 
assay together with common molecular and cultivation methods is crucial to fulfilling 
international biodefense regulations for rapidly and reliably identifying biological threat 
agents. In the future, the Luminex assay may also be considered for detecting Brucella 
in clinical samples. 
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 Tables and Figures 3.8
Table 1. Bacterial strains 
 
Bacteria were inactivated by 3% formalin, heat (60 °C for >20 h) or gamma (γ) irradiation (30-40 kGy). SL = Spiez 
Laboratory (Federal Office for Civil Protection, Spiez, Switzerland). RKI = Robert Koch Institute (Berlin, Germany).  
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Table 2. Specificity of the developed bead-based Luminex assay 
 
Luminex LOD was defined as two times the mean fluorescence intensity of the blank (mean blank = 20) and used as 
the threshold for positive results. Values in bold indicate positive results. Classification of O-antigens [4, 26–29, 41–
50]: A = α1,2-linked 4-amino-4,6-dideoxy-α-D-mannopyranosyl subunits, M = α1,3-linked and α1,2-linked 4,6-
dideoxy-4-formamido-α-D-mannopyranosyl residues, D = different O-antigen structure compared to Brucella, 
R = ‘rough’ LPS (no O-antigen). Meikle et al. 1989
1
, Adone et al. 2011
2
, Corbel 2006
3
, Wang et al. 2011
4
, Crich and 
Vinogradova 2007
5
, Watson et al. 1992
6
, Perry et al. 1986
7
, Caroff et al. 1984
8
, Bundle et al. 1984
9
, Skurnik et al. 
2000
10
, Velasco et al. 1996
11
, Perry and Bundle 1990
12
, Burtnick et al. 2002
13
, Perry et al. 1995
14
, Kenne et al. 
1982
15
. 
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Figure 1. Antigen-binding properties of the generated Brucella LPS-specific mAbs 
(A) Reactivity of the produced mAbs with extracted B. melitensis or B. abortus LPS in ELISA. (C) Western 
blot staining-patterns obtained with mAbs 10G1, 3D12 and 1E2 after SDS-PAGE of extracted 
B. melitensis and B. abortus LPS. (B) Indirect immunofluorescent staining of inactivated B. melitensis 
(16 M) cells by mAbs 3D12 and 10G1. The upper panel shows DNA staining with DAPI, the middle panel 
Alexa 568-specific immunofluorescence staining and the lower panel merged pictures of both stainings. 
(D) Reactivity of mAb 3D12 with gamma, formalin and heat inactivated B. melitensis (16 M) and 
B. abortus (544) cells in ELISA. 
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Figure 2. Comparative testing of mAb pairs in an antigen capture ELISA 
To evaluate optimal antibody combinations, each of the 11 mAbs was used as a capture or detection 
(biotin-conjugate) antibody at a concentration of 10 µg/mL. Optical densities were measured for each 
antibody combination using gamma-irradiated B. melitensis (16 M) cells at a concentration of 
10
7 
cells/mL. 
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Figure 3. Comparison of the sensitivity of the bead-based Luminex immunoassay (A) and 
the corresponding antigen capture ELISA (B) 
Assay sensitivities were determined by analysing serial dilutions of inactivated B. melitensis (16 M, γ), 
B. abortus (544, γ) and B. suis (1330, formalin) cells. Dashed lines indicate the assay dependent limit of 
detection (LOD) defined as mean blank (i.e., the no-antigen control) plus three times the standard 
deviation (SD). 
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Figure 4. Multiplexed Luminex immunoassay for detecting potential bioterror agents, 
B. melitensis, B. anthracis, F. tularensis and Y. pestis 
(A) Test samples contained B. melitensis 16 M (Bm, 5 x 10
5
 cells/mL), B. anthracis PXO1+ 
(Ba, 5 x 10
5
 cells/mL), F. tularensis 6223 (Ft, 5 x 10
5
 cells/mL) and Y. pestis CO92 (Yp, 5 x 10
4
 cells/mL) 
cells in PBS either alone or in combination. In (B), PBS and milk samples were spiked with all four 
bacterial species and used at a concentration of 2.5 x 10
6
 cells/mL. MAbs 3D12, MTA1, T14 and YPF19, 
coupled to distinct magnetic beads, were used as capture antibodies and the biotinylated mAbs 10G1, 
MTD6, FB11 and YPF19 were used for detection. Reporter dye fluorescence intensities measured for 
each bead set are shown. Dashed lines indicate the limit of detection (LOD) defined as mean blank plus 
three times the standard deviation. 
 
.
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Additional file 1. Additional bacterial strains 
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Bacteria were inactivated by 3% formalin, 10% formaldehyde or not. NCTC = National Collection of Type Cultures 
(London, UK), ICM = Instituto cantonale die microbiologica, Bellinzona (Bellinzona, Switzerland), DRDC = Defence 
Research and Development Canada (Ottawa, Canada), IVB,Z = Institut für Veterinärbakteriologie der Universität 
Zürich (Zurich, Switzerland), IVB,B = Institut für Veterinärbakteriologie der Universität Bern (Bern, Switzerland), KSBL 
= Kantonsspital Liestal (Liestal, Switzerland), KSA = Kantonsspital Aarau (Aarau, Switzerland), USCRP = U.S. 
Critical Reagents Program, SIBA = Sampling and Identification of Biological Agents, Isolate from Profiency Test 2009, 
RKI = Robert Koch Institute, Isolates from Profiency Tests (EQADeBa, QUANDHIP, Berlin, Germany), ATCC = 
American Type Culture Collection. 
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Additional file 2: Specificity of the developed bead-based Luminex immunoassay for 
B. anthracis, F. tularensis and Y. pestis 
MAb pairs MTA1/MTD6 [19], YPF19/YPF19 [22] and T14/FB11 [23] were analysed for their specific 
detection of B. anthracis, Y. pestis and F. tularensis, respectively. Coating mAbs (6 µg) were coupled to 
5 x 10
5
 magnetic beads (Bio-Plex Pro Magnetic COOH Beads, Biorad). The working concentration was 
40 beads/µL in blocking buffer (1% BSA in PBS) with 50 µL per well. Each bead containing well was 
incubated for 2 hours with 50 µL bacterial samples (Bacillus and Francisella spp., 5 x 10
6
 cells/ml, 
Yersinia spp., 5 x 10
5
 cells/mL) on a microplate shaker at 37 °C in the dark. Plates were washed with PBS 
containing 0.05% Tween-20 and the beads incubated in 50 µL of biotinylated detection antibody 
(10 µg/mL in blocking buffer) for 1 hour. After repeated washing, 50 µL of a streptavidin-R phycoerythrin 
(ProZyme Inc.) solution was added and incubated for 30 min. The plate was washed and the beads 
resuspended in 125 µL of blocking buffer before loading onto the BioPlex 200 instrument (Bio-Rad 
Laboratories). Reporter fluorescence was measured and expressed as mean fluorescence intensity of at 
least 100 beads per region. Dashed lines indicate the assay dependent limit of detection (LOD) defined 
as mean blank (i.e., the no-antigen control) plus three times the standard deviation (SD). Data were 
collected from three independent experiments in duplicates. 
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 Abstract 4.1
Background 
Brucella spp., the causative agent of brucellosis, leads to infections predominantly in 
livestock and dogs and accidentally in humans with B. melitensis, B. abortus, B. suis, 
B. canis, B. ovis and B. neotomae representing the six classical species. In the absence 
of a safe and effective vaccine for humans the disease is mainly treated with a 
combination of antibiotics. However, the diagnosis of a brucellosis infection is difficult 
and all methods (cultivation, serology and molecular detection tools) have certain 
drawbacks. Our aim was to identify protein targets for the use in antigen detection 
assays or as subunit vaccine components. Our strategy was in particular aiming at the 
generation of monoclonal antibodies (mAbs) against cell surface structures for detailed 
antigen characterisation and the development of immunological antigen detection 
systems. For the generation of mAbs, we used an approach, immunisation with whole 
bacterial cells, which has been successful in our hands with a range of different 
pathogens yielding mAbs against a variety of cell surface antigens. 
 
Results 
For the identification and characterisation of cell surface proteins, sets of mice were 
immunised with inactivated whole Brucella cells and animals showing reactivity with 
protein antigens in Western blotting were used for the generation of B cell hybridomas. 
However, all hybridomas selected based on reactivity with whole Brucella cells in ELISA 
produced antibodies specific for the O-antigen of lipopolysaccharide (LPS), but not for 
surface proteins. Therefore a peptide microarray covering 40 selected Brucella proteins 
was evaluated as alternative screening tool. However, neither sera from mice 
immunised with whole Brucella cells, nor sera from cattle naturally infected by Brucella 
bacteria showed significant reactivity with the sets of 15 amino acid long overlapping 
linear peptides of the array. 
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Conclusion 
Our Western blotting analyses showed that both whole cell immunisation of mice and 
natural infections of cattle with Brucella bacteria lead to the generation of serum 
antibodies against LPS, but also against a range of Brucella protein antigens. However, 
our approach to select hybridomas secreting mAbs against these proteins by whole cell 
ELISA failed. Using a peptide microarray covering 40 selected Brucella proteins did not 
turn out to be a viable alternative screening method. These results indicate that the 
immunogenicity of Brucella cell surface proteins is low and that immunisation with 
recombinantly expressed cell surface proteins may therefore be the best approach to 
generate mAbs against them.  
 
 
 
 
 
Keywords 
Brucellosis, immunogenic proteins, monoclonal antibodies, peptide microarray  
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 Introduction 4.2
Brucellosis, one of the leading bacterial zoonosis worldwide, is causing abortions and 
infertility in animals [1, 2]. A wide range of animals are affected, with B. melitensis 
(sheep/goats), B. abortus (cattle), B. suis (pigs), B. canis (dogs), B. ovis (sheep) and 
B. neotomae (desert wood rat) being the six major Brucella species [3]. Humans, as 
accidental hosts, present with an acute febrile illness with the potential for chronification 
of the disease [1]. Human infections are acquired through direct or indirect contact with 
domestic livestock (sheep, goats, cattle, pigs) and dogs or through animal products 
(unpasteurised milk, raw meat). Each year half a million new human cases are 
estimated, causing high morbidity and economic losses [2, 3].  
 
Three life attenuated vaccines, S19, RB51 and Rev1 [4–6] are used in livestock to 
control the disease but are infectious for humans [7–9]. For treating brucellosis 
infections in humans, antibiotics are used but relapses due to persistence of Brucella in 
macrophages and the resulting chronification requires extended treatment regimens 
[10]. A large number of serological assays e.g. agglutination tests, ELISAs, rapid 
point-of-care assays are available for diagnostics together with molecular detection 
tools. However, cultivation methods to isolate and identify Brucella spp. are still the gold 
standard in laboratory diagnosis [11–13]. Since, all tests have certain drawbacks e.g. 
long cultivation times, risk of infection, inefficiency, low specificity, inconsistency and 
costs [12, 13] and difficulties in detecting ‘rough’ Brucella [14, 15], new antigen 
detection tools have to be developed. Furthermore, no protective and safe vaccine is 
available for humans [16]. The identification of immunodominant cell surface antigens 
represents a promising approach for the development of both protein-based detection 
systems and a subunit vaccine [16–22]. 
 
The major aim of this study was to identify Brucella species-specific immunodominant 
cell surface proteins through serum analyses and the generation of mAbs from mice 
immunised with whole Brucella cells. 
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 Materials and Methods 4.3
Ethics statement 
This study was carried out in strict accordance with the Rules and Regulations for the 
Protection of Animal Rights (Tierschutzverordnung) of the Swiss Bundesamt für 
Veterinärwesen. The protocol was ethically approved by the kantonale Veterinäramt 
Basel-Stadt, Switzerland (Permit Number: 2375). 
 
Bacterial strains 
B. melitensis (NCTC 10094 16 M) and B. abortus (NCTC 10093 544) strains inactivated 
by 3% formalin, heat (60 °C for >20 h), or through gamma (γ) irradiation (30-40kGy) 
were used [23].  
 
Cattle serum 
Serum samples of cattle were collected in 2011 during a serological brucellosis study in 
livestock in Northern Togo [24]. Briefly, sera were tested by the Rose Bengal test (RBT) 
and by indirect ELISA (iELISA, CHEKIT Brucellose Serum ELISA Test Kit, IDEXX 
Laboratories, ME, USA) for classification of positive and negative serum. Twenty-five 
bovine sera were selected to analyse their specific immunological profile by ELISA and 
Western blotting. Nine sera were tested positive by iELISA and the RBT (double 
positive), five tested positive only by iELISA (single positive) and eleven tested negative 
in both assays (double negative). All sera were filtered through 0.22 µm filters prior to 
use. 
 
Generation of recombinant BQ and BP proteins 
Two Brucella proteins BQ (putrescine-binding periplasmic protein) and BP 
(spermidine/putrescine-binding periplasmic protein) were produced recombinantly by 
Lionex (Braunschweig, Germany). Protein sequences are listed below. 
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BQ (BMEI0411, PotF truncated, 342 aa) 
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPTLQERVVNIYNWSDYIDDSILKD
FTKETGIKVVYDVYDSNEILETKLLAGGSGYDLVVPSGEFLGRQIPAGVFLKLDKDKLPN
LKNMWDEISTRAATYDPGNEYSVNYMWGTTGIGYNKAKIKEALGTDTIDSWDVLFDPE
KTAKLKDCGIYLLDSASEMLRPALNYLGLDPNSPSPDDLQKAQDLYLKIRPNIRKFHSS
EYINALANGDICMAVGYSGDIFQARDRAEKAKQGVEIGYSIPKEGALIWFDQMAIPADA
KHVPEALEFMNYMMRPEVAAKASNYVFYANGNKASQKFIDKEILDDPEIYPSDEVMKK
LFVPTPYDTKTQRVVTRAWTKIVTGQ 
 
BP (BMEII0923, PotD truncated, 323 aa) 
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPTLRDLTVASWGGNYQDAQREI
YFKPFAEKTGKPLLDESWDGGYGVIQSKVKAGSPNWDVVQVEAEELALGCADGLYEK
IDWDKVGGKDKFLDSAVNDCGVGAIVWSTAIAYNGDKLKDGPKSWADFWDVKKFPGK
RSLRKSAKYTLEFALMADGVDKDDVYDVLSTPEGVDRAFKKLDELKPHIVWWEAGAQ
PLQLLASDEVVMASAYNGRITGINRSEGKNFKVVWPGSIYAVDSWVILKGAENKDAGL
DFIAFASEPEHQVKLPKYVAYGLPNKEAAAKVPEEYAADLPTAKANMKDALALDVDFWI
DHSEELTKRFNAWLAQ 
 
Immunisation and generation of monoclonal antibodies 
Immunisation of mice and the production of monoclonal antibodies were performed as 
described elsewhere [23]. Briefly, twelve transgenic Ig-tg mice [25] were immunised 
three times subcutaneously (s.c.) with 109 inactivated whole B. melitensis and 
B. abortus cells per mL adjuvanted with the Sigma Adjuvant System® (SAS, Sigma 
Aldrich) or PBS. Mouse B3 (2.3) and D2 (4.2) immunised with γ irradiated B. melitensis 
and formalin inactivated B. abortus, respectively, were chosen for monoclonal antibody 
(mAb) production [23].  
A second set of ten transgenic Ig-tg mice (2 per group) was immunised three times s.c. 
with 109 heat inactivated B. melitensis cells per mL in SAS (group A) or PBS (group B), 
heat inactivated B. abortus in SAS (group C) or PBS (group D) and γ irradiated 
B. melitensis in SAS (group E). Two additional booster injections were administered, 
using the same bacteria formulations. The first injection was given s.c. in SAS for 
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mouse A1-E1 and intravenously in PBS for mouse A2-E2, the second for all mice s.c. in 
SAS. Mouse A1 and E1 were chosen for the production of mAbs. An additional mouse 
was included to collect serum before immunisation (pre immune serum). 
A third set of four mice (2 per group) were immunised three times s.c. with 20 µg 
recombinant protein BQ (group A) and BP (group B) per mouse both adjuvanted in 
SAS.  
Serum was taken always at the day of immunisation (pre immune serum) and three 
weeks after each immunisation (immune serum).  
 
ELISA 
An indirect ELISA (iELISA) on whole B. melitensis and B. abortus cells was performed 
as described elsewhere [23]. Briefly, 107 heat treated or γ irradiated whole B. melitensis 
and B. abortus cells per mL in PBS were coated overnight at 4 °C in Maxisorp™ 
microtitre plates (Nunc, Thermo Scientific). Wells were then blocked with 5% milk 
powder in PBS or Superblock buffer (SuperBlock™ (PBS) Blocking Buffer, Thermo 
Scientific) before applying appropriate dilutions of mouse or bovine serum, respectively. 
A horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (γ chain specific, 
1:4,000, Sigma Aldrich) or alkaline phosphatase (AP) conjugated goat anti-mouse IgG 
(γ chain specific, 1:10,000, Sigma Aldrich) antibody was used for detection of mouse 
serum, an alkaline phosphatase (AP) conjugated rabbit anti-bovine IgG (Fc fragment 
specific, 1:10,000, Jackson ImmunoResearch) antibody for the detection of bovine 
serum. ABTS substrate (ABTS® Peroxidase Substrate System, KPL) or 1 mg/mL 
p-Nitrophenyl phosphate (pNPP, Sigma Aldrich) in substrate buffer was applied and the 
optical density (OD) of the reaction product was recorded at 405 or 570 nm using a 
microplate reader. Serum was tested on recombinant proteins as described above by 
applying mouse serum on 10, 5, 2.5 and 1 µg/mL pre-coated BQ and BP proteins.  
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Immunofluorescence assay 
As described before [23], the immunofluorescence assay (IFA) was performed using 
10 µL heat inactivated or γ irradiated B. melitensis and B. abortus cells fixed by 4% 
paraformaldehyde (Sigma Aldrich) and 10% PBS diluted in distilled water to pre-coated 
Poly-L-Lysin IFA slides (Diagnostic Microscope Slides ES-242B-AD-CE24, Thermo 
Scientific). Diluted serum (1:100) was applied for 1 hour.  
 
SDS-PAGE gel electrophoresis, Western blotting and silver staining 
Western blot analysis was done as described elsewhere [23]. Briefly, mouse serum 
(before and after immunisation) was tested in a 1:100, 1:200 and/ or 1:1,000 dilution in 
PBS on inactivated (formalin, heat or γ) B. melitensis and B. abortus lysate (108 or 
5 x 108 bacteria/mL) or 10 µg recombinant BQ and BP proteins per gel (200 µL). Bovine 
serum diluted 1:100 and 1:1,000 in Superblock buffer (SuperBlock™ (PBS) Blocking 
Buffer, Thermo Scientific) containing 0.05% Tween-20 was tested on B. melitensis (γ) 
and B. abortus (γ) lysate (5 x 108 bacteria/mL) after blocking with Superblock buffer. For 
detecting mouse serum a Horseradish peroxidase (HRP) conjugated goat anti-mouse 
IgG (γ chain specific, 1:4,000, Sigma Aldrich) or alkaline phosphatase (AP) conjugated 
goat anti-mouse IgG (γ chain specific), 1:10,000, Sigma Aldrich) antibody was used. An 
alkaline phosphatase (AP) conjugated rabbit anti-bovine IgG (Fc fragment specific, 
1:10,000, Jackson ImmunoResearch) antibody was used to detect bovine serum. For 
the development of the assay the ECL (Pierce® ECL Western blotting substrate, 
Thermo Scientific) or the NBT/BCIP (BCIP 100X (5-bromo-4-chloro-3-indolyl phosphate) 
and NBT 100X (nitroblue tetrazolium, Biorad) system was used.  
After separating proteins from B. melitensis (γ) lysate on a SDS-PAGE gel, the gel was 
stained with silver ions (SilverQuest™ Silver Staining Kit, Invitrogen) for protein 
visualisation. Stained protein bands of interest were excised, destained and sent for 
nano-LC mass spectrometry analysis (PMSCF, University Bern, Switzerland). 
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PEPperCHIP® design and performance of a peptide microarray 
A new peptide microarray technology called PEPperCHIP® (PEPperPRINT, Heidelberg, 
Germany) was used to identify immunodominant antigens of Brucella species. 
Therefore 40 Brucella proteins (mainly membrane proteins listed in Table 1) were 
selected using GeneOntology and Patric databases together with a literature research 
for outer membrane proteins (OMPs) of Brucella [17, 26–34]. Same proteins from 
different Brucella spp. were included to cover sequence alterations. All proteins were 
translated into 15 amino acid (aa) peptides with a peptide-peptide overlap of 11 aa 
resulting in 3,521 different peptides. The C- and N-terminus of the antigens were 
thereby elongated by neutral GS linkers to avoid truncated peptides. In a next step all 
peptides were spotted as duplicates onto a polymer coated surface (10 nm PEGMA) 
with 2 x β-alanine and 1 x aspatic acid as linker. FLAG and HA peptides were spotted 
as control peptides. The unique PEPperCHIP® microarrays were produced by 
PEPperPRINT and the assay was performed according to their protocol from 2012. 
Briefly, for analyses of mouse serum, slides were pre stained with 1 mL Cy5 (DyLight 
649) conjugated goat anti-mouse IgG (H&L, Rockland) antibody diluted 1:5,000 in 
staining buffer (PBS, pH7.4 with 0.05% Tween 20 and 0.1% BSA) for 30 min and 
blocked afterwards with 1 mL PBS containing 0.05% Tween-20, 1% BSA for 1 h. PBS 
with 0.05% Tween-20 was used as washing buffer. Pre immune and immune serum of 
mouse A1 (B. melitensis, heat) was used in a 1:200 dilution in staining buffer and 
applied after each other (1. pre immune, 2. immune serum) on the same slide over night 
at 4 °C. The slide was washed and the fluorescence intensity was measured in 
between. For detection the same Cy5 antibody was used and fluorescence intensities 
were measured using a microarray scanner (GenePix 4000B, Molecular Devices). The 
parameters were set as following: gain = 600, power = 100%, pixel size = 20 µm, lines 
to average = 5, focus = 30 µm. For the staining of the FLAG and HA control peptides, 
Cy5 conjugated monoclonal anti-HA (12CA5) and Cy3 conjugated anti-FLAG (M2, both 
1:1,000) antibodies were used, both provided by PEPperPRINT. Data measured by the 
GenePix microarray scanner was further analysed using the PepSlide® Analyzer 
Software (Sicasys, Heidelberg, Germany) to obtain fluorescence intensities of each 
spotted peptide. 
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Bovine serum D (double positive) and V (double negative) were tested as mentioned 
above in a 1:500 dilution on individual microarrays. Superblock buffer (SuperBlock™ 
(PBS) Blocking Buffer, Thermo Scientific) containing 0.1% Tween-20 was used for 
blocking, Superblock buffer containing 0.05% Tween-20 for washing and staining. For 
the pre staining and detection step a Cy3 (DyLight 549) conjugated goat anti-bovine IgG 
(H&L, 1:100, Jackson ImmunoResearch) antibody was used. 
 
Statistical analysis 
Basic calculations (mean values, differences in signal intensities) were performed in 
Microsoft Excel. Figure assembly, data transformation and linear/ non-linear regression 
were performed with GraphPad Prism whereas figures containing Western blot and 
immunofluorescence assay data were generated with Adobe Photoshop CS. 
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 Results 4.4
Analysis of immune responses after whole cell immunisation  
Immunisation of mice with inactivated whole Brucella cells induced the production of 
Abs against LPS and Brucella proteins [23]. All immune sera tested showed dose 
dependent development of IgG antibodies reactive with inactivated whole B. melitensis 
cells in ELISA (Fig. 1A) and produced a circular surface staining with fixed B. melitensis 
cells in immunofluorescence microscopy (Fig. 1B). In Western blotting analyses with 
B. melitensis and B. abortus lysate all immune sera stained multiple protein bands 
(Fig. 1C). However, marked differences in staining patterns were observed. In general 
immunisation with γ irradiated bacteria (immunisation groups A and B) induced primarily 
antibodies reacting with protein antigens with a molecular weight >24kDa. In 
comparison, sera from mice immunised with formalin inactivated bacteria (immunisation 
groups C and D) reacted also strongly with some smaller antigens. Reactivity with 
B. abortus lysate was for all immune sera much weaker than with B. melitensis lysate. 
Two fusions performed with spleen cells of mice immunised with γ irradiated bacteria 
(B3) or formalin inactivated bacteria (D2) and screened by whole cell ELISA resulted in 
the generation of LPS- but not protein-specific mAbs [23]. 
 
In a next step new sets of mice were immunised with inactivated whole Brucella cells 
with or without adjuvants. Individual animals tested positive in whole cell ELISA, 
Western blotting and immunofluorescence assay (Fig. 2) were selected for the 
generation of mAbs employing a different screening strategy.  
In this alternative approach for the identification of immunodominant cell surface 
proteins, Western blot analyses (Fig. 3A) were used to identify proteins reactive with the 
immune sera. Nine protein bands corresponding in size to the stained bands were cut 
out from a silver stained SDS-PAGE gel (Fig. 3B). Nano-LC mass spectrometry 
(LC-MS) analyses identified in eight of the nine excised gel blocks a predominant 
protein with a sequence coverage of 24 to 77% and a protein abundance above 50 
(Table 2). The calculated molecular weights of these proteins correlated with those 
observed in the Western blot analyses. The identified proteins are known to be located 
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in various compartments of the bacteria (ER, mitochondria, ribosome, cytoplasm, inner 
membrane and periplasm), but are most likely not associated with the cell surface. 
 
Sera from mice belonging to the immunisation groups A, B, C, D, E (Fig. 2) were also 
tested for reactivity with the two recombinant Brucella proteins BQ and BP in ELISA and 
Western blotting (Fig. 4). Six mouse sera reacted with BQ (A1, A2, C1, C2, D1, D2) and 
one with BP (E1) in both assays with a specific staining for BQ and BP at 42kDa and 
40kDa, respectively, in Western blot analysis (Fig. 4B). Based on these results mouse 
A1 and E1 were selected for the generation of mAbs. However, when screened by 
ELISA with recombinant BQ and BP, none of the culture supernatants yielded a positive 
signal. 
 
Immunisation with recombinant Brucella antigens 
Mice immunised with the recombinant Brucella proteins BP and BQ and sera were 
tested for reactivity with recombinant BQ and BP in ELISA and Western blot analysis. 
While strong and specific IgG responses against the recombinant proteins were 
observed in ELISA (Fig. 5A) and Western blotting (data not shown), no binding to 
Brucella cells was found in the cell ELISA (Fig. 5B). Also in Western blot analyses with 
Brucella lysate, no reactivity was observed (Fig. 5C). 
 
Characterisation of the immunological profile of bovine serum 
Bovine sera from a serological brucellosis study in northern Togo were tested for 
protein-specific immune responses in a whole cell ELISA. Sera had been tested before 
both by the Rose Bengal test and with a commercial brucellosis serum ELISA Test Kit. 
Nine double positive sera (A-I), five single positive sera (J-N) and eleven double 
negative sera (O-Y) were tested in ELISA on whole Brucella cells (Fig. 6). All double 
positive sera (A-I) and one single positive serum (K) showed high antibody titre against 
B. melitensis and B. abortus cells above a threshold of OD = 0.6. 
When the bovine sera were tested in Western blot analysis on B. melitensis and 
B. abortus lysate (Fig. 7), the strongest signals were seen with the double and single 
positive sera A-N. While most of these tracings were characteristic for a LPS-specific 
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staining [23], some protein bands were also stained. Certain proteins seemed to be 
recognised by all single- and double-positive sera, but not by double negative sera, 
which showed only sporadic staining of a few proteins. 
 
Evaluation of the PEPperCHIP® peptide microarray technology for screening  
To avoid signals associated with the immunodominant LPS, a microarray 
(PEPperCHIP®) covering peptides derived from 40 selected Brucella proteins was 
evaluated as screening tool. Serum of mice immunised with whole Brucella cells (serum 
A1) and serum of naturally infected cattle (positive serum D and negative serum V) 
were selected. Although, all immune sera were reactive with Brucella proteins in ELISA 
or Western blotting (Fig. 2, 5, 7) only marginal reactivities with the Brucella 
protein-derived peptides were observed (Suppl. Fig. 1-2). 
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 Discussion 4.5
Brucellosis is affecting a variety of domestic animals and wildlife with humans being 
infected accidentally. With 500,000 new cases every year, brucellosis is one of the 
major zoonoses occurring worldwide [1, 3]. Since early and intensive antibiotic 
treatment is crucial for efficiently treating human infections in the absence of a safe and 
effective vaccine [10, 16], a fast and precise diagnosis of brucellosis is important. 
Cultivation and the identification of the causative agent are required beside serological 
assays used to identify Brucella-specific antibodies. Mostly, whole cells, 
lipopolysaccharide (LPS) or the O-antigen of LPS are used as target antigen [11–13]. 
Since B. canis, capable of infecting humans [3], and B. ovis are both expressing the 
‘rough’ version of LPS [14, 15] and cross-reactivities are observed, especially with 
Y. enterocolitica O9, serological assays based on ‘smooth’ LPS can lead to false 
negative or false positive results, respectively [35–38]. 
 
Primary aim of our project was to contribute to attempts to identify Brucella spp. specific 
immunodominant proteins [16–22] to support development of new tools for brucellosis 
control. Definition of new protein targets can in particular accelerate development of 
new antigen detection assays, candidate vaccines and molecular fine typing methods 
for epidemiological studies.  
 
In this context, we were mainly interested in protein antigens at the surface of 
Brucella spp. that are accessible to the humoral immune system. Therefore, we have 
immunised mice with inactivated whole Brucella cells. The generated immune sera were 
highly reactive with whole Brucella cells and as expected, strong antibody responses 
against the O-polysaccharide of ‘smooth’ LPS were observed [39]. However, in addition, 
Western blotting analyses with Brucella cell lysates revealed that also protein-specific 
serum antibodies were generated. Using this immunisation approach for other bacterial 
pathogens, such as Mycobacterium ulcerans and Neisseria meningitidis (Diaz et al. 
[40], Ispasanie et al. (unpublished work)), has allowed us to generate panels of mAbs 
against ranges of cell surface proteins. In contrast, we obtained, in the case of the 
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Brucella immunised mice, only B cell hybridoma cell lines producing LPS-specific mAbs 
[23]. It might be that the screening on immobilised whole cells hampered the selection 
of cell lines producing anti-protein antibodies, since LPS might mask very efficiently the 
accessibility of protein antigens at the surface of Brucella cells [27, 41]. On the other 
hand, immune sera showed reactivities with Brucella proteins in Western blotting 
analyses. However, when we identified protein bands stained in Western blot analysis 
with Brucella lysates by mass spectrometry, we found that immune responses were 
directed against proteins located in various compartments of the bacterium (Table 2), 
but most likely not associated with the bacterial surface. This might be explained by 
processing of the bacterial cells after immunisation making immunodominant proteins, 
located inside the cell, accessible to the immune system. 
 
In another approach we tested sera of whole cell immunised mice against the two 
recombinantly expressed periplasmic Brucella proteins BQ and BP. Some of the sera 
were indeed showing reactivities against BQ or BP in ELISA and Western blot analysis 
(Fig. 4) and two mice were selected for the production of mAbs by B cell hybridoma 
technology. However, when screened in ELISA on recombinant proteins, no B cell 
hybridoma line secreting BQ- or BP-specific mAbs could be identified, although, the 
immune sera of the mice used for hybridoma generation were positive in the same 
ELISA. We do not have an explanation for this, since microscopic analyses revealed 
that the fusion process per se worked and large numbers of hybridomas were 
generated. 
 
Since the attempts to obtain protein-specific mAbs through whole cell immunisation had 
failed, we immunised mice in a next step directly with the two recombinant proteins BQ 
and BP, resulting in high IgG serum titres against both proteins in ELISA and 
protein-specific signals in Western blot analysis. However, no cross-reactivities could be 
observed with whole cells in ELISA or with Brucella lysate in Western blotting (Fig. 5). 
ELISA negativity might be related to the periplasmic localisation of the two proteins. 
Lack of cross-reactivity in Western blotting is more difficult to explain but it might be that 
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mainly conformational epitopes were recognised by serum antibodies, prohibiting the 
binding of the denatured protein in Western blot analysis. 
 
To escape from the dominance of LPS reactivities in the hybridoma screening process, 
we evaluated the use of peptide microarrays [42] containing peptides derived from a 
series of Brucella proteins, mainly membrane proteins and outer membrane proteins. 
However, sera of mice immunised with whole Brucella cells showed only marginal 
binding to a few peptides, most likely representing unspecific background reactivities. It 
might be that the serum antibodies were recognising primarily conformational and 
discontinuous epitopes, not mirrored by the relatively short (15 amino acids) linear 
peptides. Furthermore, as indicated by LC-mass spectrometry analysis whole cell 
immunisation may, in the case of Brucella bacteria, not trigger preferentially antibody 
response against cell surface proteins. Serum of mice immunised with recombinant BQ 
or BP proteins was not tested since no BQ- or BP-derived peptides were present on the 
microarray. Since the microarray assay did not yield strong signals with the immune 
sera, no attempts were made to screen hybridoma supernatants with this method. 
 
In a last step, we screened bovine serum antibody responses in the course of natural 
Brucella infections. Sera had been categorised before according to their infection status 
determined by the Rose Bengal test and a commercial serological ELISA test. All 
double positive and one single positive sera recognised whole Brucella cells in ELISA. 
When tested on Brucella lysate in Western blotting analyses, strong signals were 
observed both with LPS and a range of protein antigens. It is remarkable that some 
proteins were stained by practically all sera from Brucella infected animals, but not from 
uninfected controls. While the identification of these proteins by mass spectrometry 
would represent a promising approach for lining up immunodominant proteins, we did 
not follow this up, since we became aware of similar comprehensive studies performed 
by Wareth et al. [43]. Lack of reactivity of the cattle sera with the microarray may 
indicate that cell surface proteins are in the case of Brucella bacteria not 
immunodominant. 
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 Tables and Figures 4.7
Table 1. List of Brucella proteins 
No. Protein Region AC
1
 (GenBank) 
1 membrane protein permease of the drug/metabolite transporter (DMT) 
superfamily 
WP_004686021 
2 transporter, dme family permease of the drug/metabolite transporter (DMT) 
superfamily 
AAL51352 
3 cytochrome C biogenesis protein cytochrome c biogenesis protein CcdA WP_002966050 
4 transporter, dme family permease of the drug/metabolite transporter (DMT) 
superfamily 
AAL53681 
5 preprotein translocase subunit TatC sec-independent protein secretion pathway component TatC  WP_002964014 
6 transporter, dme family permease of the drug/metabolite transporter (DMT) 
superfamily 
AAL51687 
7 cadmium transporter divalent metal cation (Fe/Co/Zn/Cd) transporter WP_004685799 
8 cadmium transporter divalent metal cation (Fe/Co/Zn/Cd) transporter WP_002964670 
9+10 sodium alanine symporter Na+/alanine symporter WP_004684997 
11 cobalt-zinc-cadmium resistance 
protein czcd 
Co/Zn/Cd efflux system component AAL52619 
12+13 transporter permease of the drug/metabolite transporter (DMT) 
superfamily 
WP_004684405 
14 MATE efflux family protein Na+-driven multidrug efflux pump AIJ86325 
15 MATE efflux family protein  Na+-driven multidrug efflux pump AIJ55733 
16 biopolymer transport protein ExbB TonB-system energizer ExbB WP_002964760 
17 MATE family efflux transporter subfamily of the multidrug and toxic compound extrusion 
(MATE)-like proteins 
WP_004685435 
18 membrane protein permease of the drug/metabolite transporter (DMT) 
superfamily 
WP_002966348 
19 C4-dicarboxylate ABC transporter 
permease 
TRAP transporter, 4TM/12TM fusion protein WP_004685691 
20 C4-dicarboxylate ABC transporter 
permease 
TRAP transporter, 4TM/12TM fusion protein WP_004685691 
21 OmpA-like transmembrane domain 
protein 
opacity protein and related surface antigens ACD73018 
22 31 kDa outer-membrane 
immunogenic protein precursor 
opacity protein and related surface antigens  AAL51583 
23 outer-membrane immunogenic 
protein 
opacity protein and related surface antigens AEW14628 
24 outer-membrane immunogenic 
protein 
opacity protein and related surface antigens EFG36419 
25 outer membrane protein Omp31 opacity protein and related surface antigens ADZ67646 
26 OMP31 opacity protein and related surface antigens ACV07678 
Article 2. Monoclonal antibodies against Brucella cell surface proteins 83 
 
 
27 pETOmp opacity protein and related surface antigens CCJ65172 
28 outer membrane lipoprotein omp19 protease inhibitor Inh EFG36760 
29 outer membrane protein 16 outer membrane protein OmpA and related  
peptidoglycan-associated (lipo)proteins 
AGI97133 
30 Porin Omp2b Porin subfamily AEQ08269 
31 Omp2b Porin subfamily AAX83996 
32 Omp2b Porin subfamily AHN46277 
33 TonB-dependent receptor protein TonB-dependent copper receptor EEW87781 
34 Bp26 uncharacterized conserved protein YggE ABC17803 
35+36 Dnak protein molecular chaperone DnaK AAL53183 
37 molecular chaperone Hsp70 molecular chaperone DnaK (HSP70) WP_019443743 
38 molecular chaperone Dnak RNA polymerase-binding protein DksA WP_002964154 
39 chaperone protein Dnak molecular chaperone DnaK EEH15197 
40 flagellar motor protein MotB flagellar motor protein MotB WP_004685912 
Proteins 1-20 represent membrane proteins identified by GeneOntology and PATRIC databases (GO term: 0016020), 
proteins 21-40 represent immunogenic proteins identified by Connolly et al. and He et al. [16, 17]. 
1
Accession 
number. 
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Table 2. Identification of unknown proteins by LC mass spectrometry 
Protein PMSS
1
 Peptides
2
 
Coverage
3 
[%] 
Weight
4
 
[kDa] 
Description 
Predicted 
localisation 
AC
5
 
(Swiss-Prot, 
GenBank) 
a 126.9 16 39.9 68.2 chaperone protein DnaK ER, mitochondria, 
ribosome 
Q8YE76 
b 368.6 30 68.5 57.5 60 kDa chaperonin cytoplasm Q8YB53 
c 139.0 18 46.6 54.8 ATP synthase subunit beta inner membrane Q8YJ35 
d 223.4 19 65.2 42.6 probable sugar-binding 
periplasmic protein  
periplasm Q8YCE2 
e 50.7 8 26.4 37.1 Leu/Ile/Val-binding protein 
homolog 1 
periplasm Q8YJ23 
f 102.3 10 50.2 31.5 31 kDa immunogenic 
protein 
periplasm P0A3T2 
g 89.5 10 53.0 23.4 probable transaldolase cytoplasm Q8YJ42 
h 66.7 8 77.0 18.7 bacterioferritin cell P49944 
i 16.2 2 23.7 10.5 50S ribosomal protein L23 ribosome Q8YHN8 
Nine unknown proteins (a-i) cross-reactive with immune serum of mice immunised with inactivated whole Brucella 
cells in Western blot analysis were identified by nano-LC mass spectrometry. Following parameters were measured: 
1
protein abundance (semi quantitative measure), 
2
protein unique peptides, 
3
percent coverage of the entire protein 
sequence and 
4
molecular weight. 
5
Accession number. 
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Figure 1. Serum reactivity of mice immunised with whole Brucella cells inactivated by 
formalin treatment or gamma irradiation 
Four groups of mice were immunised three times with inactivated whole Brucella cells and serum was 
tested in ELISA, Western blot and immunofluorescence analysis (IFA). Group 1 (A) received gamma (γ) 
irradiated B. melitensis in PBS, group 2 (B) γ irradiated B. melitensis with Sigma Adjuvant System, group 
3 (C) formalin inactivated B. melitensis in PBS and group 4 (D) formalin inactivated B. abortus in PBS. (A) 
Pre immune (Pre) and immune serum after the third immunisation (3. Imm) were pooled (3 mice each) 
and serial dilutions (4-fold, starting from 1:100) tested in ELISA on γ irradiated B. melitensis. (B) Immune 
serum (1:100) of mouse B3 and D2 and PBS as negative control (red) were tested in IFA on 2.5 x 10
8
 
fixed B. melitensis (γ) per mL. Nuclei were stained with DAPI (blue). Merged pictures of both stainings are 
shown in the right panel. Original magnification X160. (C) Pooled pre immune (Pre) and individual 
immune sera (1:200) after the third immunisation (group A-D) were tested on formalin inactivated 
B. melitensis and B. abortus (both 5 x 10
8
 bacteria/mL) lysate. 
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Figure 2. Serum reactivity of mice immunised with whole Brucella cells inactivated by 
heat treatment or gamma irradiation 
Five groups of mice were immunised with inactivated whole Brucella cells and serum was tested with 
ELISA, Western blot and immunofluorescence analysis (IFA). Group 1 (A) received heat inactivated 
B. melitensis with Sigma Adjuvant System (SAS), group 2 (B) heat inactivated B. melitensis in PBS, group 
3 (C) heat inactivated B. abortus with SAS, group 4 (D) heat inactivated B. abortus in PBS and group 5 
(E) γ irradiated B. melitensis with SAS for three times. Two additional booster injections with the same 
bacteria formulation were given, first subcutaneously (s.c.) in SAS (A1-E1) or intravenously in PBS 
(A2-E2), second for all mice (A1-E2) s.c. in SAS. (A) Individual immune sera after the fifth immunisation 
and pre immune serum before immunisation (Pre) were diluted serially (2-fold, starting from 1:50) and 
tested in ELISA on γ irradiated whole B. melitensis and B. abortus cells. (B) Pre immune serum (Pre) and 
immune serum (1:100) of mouse A2 (red) was tested in IFA on 4% paraformaldehyde fixed B. melitensis 
(heat) and B. abortus (heat) cells (both 5 x 10
7
 bacteria/mL). Nuclei were stained with DAPI (blue). 
Merged pictures of both stainings are shown in the right panel. Original magnification X160. (C) Pre 
immune (Pre) and individual immune sera after the fifth immunisation (1=1:100, 2=1:1,000) were tested 
on γ irradiated B. melitensis and B. abortus (both 5 x 10
8
 bacteria/mL) lysate. 
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Figure 3. Identification of immune reactive proteins from mice immunised with whole 
Brucella cells 
(A) Immune sera of mice (1:100, 2 mice per group) immunised three times with heat inactivated 
B. melitensis with Sigma Adjuvant System (SAS, A), heat inactivated B. melitensis in PBS (B), heat 
inactivated B. abortus with SAS (C), heat inactivated B. abortus in PBS (D) and γ irradiated B. melitensis 
with SAS (E) followed by additional booster injections with the same bacteria formulation first in SAS 
(A1-E1) or in PBS (A2-E2), second in SAS (all mice), were tested in Western blot analysis on γ irradiated 
B. melitensis (10
9
 bacteria/mL) lysate. (B) A silver stained (SilverQuest™ Silver Staining Kit, Invitrogen) 
SDS-Page gel loaded with the same B. melitensis (γ) lysate was done in parallel to visualise separated 
proteins. Bands (a-i), immune reactive with mouse serum in Western blot analysis were excised from the 
stained gel and destained according to product guidelines. Unknown proteins were identified by nano-LC 
mass spectrometry (PMSCF, University Bern, Switzerland). 
 
Article 2. Monoclonal antibodies against Brucella cell surface proteins 88 
 
 
 
 
Figure 4. Reactivity of whole cell immunised mouse serum with recombinant BQ and BP 
antigens 
Serum of mice (2 per group) immunised three times with heat inactivated B. melitensis with Sigma 
Adjuvant System (SAS, A), heat inactivated B. melitensis in PBS (B), heat inactivated B. abortus with 
SAS (C), heat inactivated B. abortus in PBS (D) and γ irradiated B. melitensis with SAS (E), followed by 
additional booster injections with the same bacteria formulation first in SAS (A1-E1) or in PBS (A2-E2), 
second in SAS (all mice), were tested in ELISA and Western blot analysis on two recombinant proteins 
(BQ and BP) of Brucella species. Pre immune serum (Pre) and individual immune sera (1:100) after the 
fifth immunisation were tested on 10, 5, 2.5 and 1 µg recombinant BQ or BP per mL in ELISA (A) and 
10 µg recombinant BQ or BP per gel in Western blot analysis (B). 
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Figure 5. Serum reactivity of mice immunised with recombinant BQ and BP 
Two groups of mice were immunised with recombinant BQ or BP proteins as adjuvanted formulation, in 
combination with the Sigma Adjuvant System (SAS). Two mice per group received three subcutaneous 
injections with 20 µg recombinant BQ (A) or BP (B) in combination with SAS. Pre immune (Pre) and 
immune serum after the third immunisation (Imm) were diluted 1:100 and tested separately in ELISA on 
10, 5, 2.5 and 1 µg recombinant BQ or BP per mL (A) and heat inactivated whole B. melitensis and 
B. abortus cells (B). Same sera (1=1:100, 2=1:1,000) were tested in Western blot analysis on 
B. melitensis (heat, 10
8
 bacteria/mL) lysate (C). Anti-LPS monoclonal antibodies (mAbs 3D12 (1) and 
10G1 (2), [23]) and PBS served as controls. 
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Figure 6. Reactivity of bovine serum with inactivated whole Brucella cells in ELISA 
Serum from cattle (livestock in Northern Togo) tested positive for Brucella species by iELISA and the 
Rose Bengal test (RBT, serum A-I), by iELISA alone (J-N) and iELISA and RBT negative control serum 
(O-Y) was serially diluted (3-fold, starting from 1:50) and analysed in ELISA on γ irradiated whole 
B. melitensis and B. abortus cells.  
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Figure 7. Reactivity of bovine serum with Brucella lysate 
Serum from cattle (livestock in Northern Togo) tested positive for Brucella species by iELISA and the 
Rose Bengal test (RBT, serum A-I), by iELISA alone (J-N) and iELISA and RBT negative control serum 
(O-Y) was tested in Western blot analysis on B. melitensis (γ, A) and B. abortus (γ, B) lysate (both 
5 x 10
8 
bacteria/mL). All sera were diluted 1:100 (1) and 1:1,000 (2). An anti-LPS monoclonal antibody 
(mAb 3D12, [23]) and PBS were included as controls. 
 
Article 2. Monoclonal antibodies against Brucella cell surface proteins 92 
 
 
 
 
Supplementary Figure 1. Screening of serum from mice immunised with inactivated 
whole Brucella cells with peptide microarrays 
Serum of mice immunised with heat inactivated B. melitensis was tested on microarrays (PEPperCHIP®) 
covering protein-derived peptides of Brucella bacteria. (A) Fluorescence intensities of immune serum 
after the fifth immunisation (dark grey) and pre immune serum before immunisation (light grey) are shown 
for all peptides. Differences in signal intensity are shown in black. (B) Original microarray scans are 
showing (from left to right) the array before applying serum (negative control), after applying pre immune 
serum, after applying immune serum and after applying Cy5-conjugated monoclonal anti-HA (12CA5) 
antibodies to stain HA control peptides surrounding the array. Serum was tested in a 1:200 dilution and 
Cy5-conjugated goat anti-mouse IgG antibodies were used for detection. Fluorescence intensity was 
measured using a microarray scanner (GenePix 4000B, Molecular Devices) with parameters set as 
following: gain = 600, power = 100%, pixel size = 20 µm, lines to average = 5, focus = 30 µm. 
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Supplementary Figure 2. Screening of bovine serum with peptide microarrays 
Bovine serum of naturally infected cattle, classified as double positive or double negative serum by the 
Rose Bengal test and a commercial iELISA was tested individually on microarrays (PEPperCHIP®) 
covering protein-derived peptides of Brucella. (A) Fluorescence intensities of double positive (dark grey) 
and double negative (light grey) serum are shown for all peptides. Differences in signal intensity are 
shown in black. (B) Original microarray scans are showing (from left to right) the array before applying 
serum (negative control), after applying double negative serum, after applying double positive serum and 
after applying Cy3-conjugated monoclonal anti-FLAG (M2) antibodies to stain FLAG control peptides 
surrounding the array. Serum was tested in a 1:500 dilution and Cy3-conjugated goat anti-bovine IgG 
antibodies were used for detection. Fluorescence intensity was measured using a microarray scanner 
(GenePix 4000B, Molecular Devices) with parameters set as following: gain = 600, power = 100%, pixel 
size = 20 µm, lines to average = 5, focus = 30 µm. 
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 Abstract 5.1
We have recombinantly expressed the 40kDa receptor-binding domain of the 
Plasmodium falciparum reticulocyte-binding homolog 2 (PfRH240) in Escherichia coli 
and used the adjuvanted purified protein to immunise mice. Using spleen cells of an 
immunised mouse we subsequently generated a set of anti-PfRH2 monoclonal 
antibodies (mAbs) by B cell hybridoma technology. All five mAbs obtained cross-reacted 
with the erythrocyte invasion ligand PfRH2, produced by schizont stage parasites, and 
yielded in immunofluorescence microscopy the expected dotted staining pattern 
characteristic for rhoptries. Nevertheless, none of the mAbs was active in an in vitro 
growth inhibition assay on its own. Furthermore, the anti-PfRH2 mAbs did not enhance 
the parasite growth inhibitory activity of mAbs specific for the cysteine-rich protective 
antigen (PfCyRPA). Also, in a P. falciparum animal infection model based on 
NOD-scid IL2Rγnull mice engrafted with human erythrocytes, anti-PfRH2 mAbs did not 
show parasite inhibitory activity.  
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 Introduction 5.2
In 2013, the WHO estimated 200 million malaria-infected people and 500,000 deaths 
worldwide [1] with Plasmodium falciparum causing most of the severe malaria cases in 
humans [2]. An effective malaria vaccine could be an important tool towards malaria 
control and elimination [3]. Since the most advanced vaccine candidate, RTS,S, showed 
only partial protection against malaria, second generation vaccines are of great need [4, 
5]. Clinical symptoms in malaria are primarily caused by toxic substances released into 
the blood stream during rupture of erythrocytes [1], hence a disease-preventing vaccine 
needs to block merozoite-erythrocyte interactions during erythrocyte invasion. Single 
antigens from blood stage parasites, including MSP1 and AMA1 tested in clinical trials, 
were not blocking erythrocyte invasion efficiently [6, 7]. However, approaches that 
targeted multiple merozoite antigens yielded promising invasion-inhibitory effects [8–
10]. 
 
Previous studies indicated that rabbits immunised with different fragments of the 
P. falciparum reticulocyte-binding homolog 2 (PfRH2) elicited inhibitory serum 
antibodies that efficiently block P. falciparum parasite invasion in vitro [2, 8, 11–16]. 
PfRH2, a member of the PfRH protein family, is a blood stage merozoite adhesin 
expressed during erythrocytic schizogony and located in the rhoptry neck of 
P. falciparum apical organelles [11–13, 17]. During merozoite invasion, PfRH2 is 
relocated from the rhoptry neck both to the moving junctions and the merozoite surface 
to bind human erythrocytes through sialic acid independent receptors [13, 18, 19]. The 
receptor-binding domain is a conserved region of 40kDa [14], identical in the two 
homologs of PfRH2 (PfRH2a and PfRH2b).  
 
In this study, the receptor-binding domain of PfRH2 (PfRH240) was recombinantly 
expressed in E. coli and used to immunise mice to generate a set of anti-PfRH2 
monoclonal antibodies (mAbs). However, none of the produced mAbs showed any 
activity in in vitro or in vivo growth inhibition assays. 
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 Materials and Methods 5.3
Ethics statement 
This study was carried out in strict accordance with the Rules and Regulations for the 
Protection of Animal Rights (Tierschutzverordnung) of the Swiss Federal Food Safety 
and Veterinary Office. The protocol was granted ethical approval by the Veterinary 
Office of the county of Basel-Stadt, Switzerland (Permit Number: 2375). 
 
Cultivation of P. falciparum parasites 
P. falciparum (strain 3D7) was cultivated as published elsewhere [20, 21]. Medium was 
supplemented with 0.5% AlbuMax™ (Life Technologies) and parasites were cultivated 
with 5% human erythrocytes received from the Swiss Red Cross (Basel, Switzerland). 
Cultures were synchronised by sorbitol [22] or percoll treatment [23] to obtain ring-stage 
parasites or schizonts, respectively. 
 
Generation of recombinant PfRH240 
The 40kDa receptor-binding domain of PfRH2, consisting of amino acids 495-860, was 
expressed recombinantly in E. coli together with a hexahistidine (His) tag as described 
elsewhere [15].  
 
Production of anti-PfRH2 mAbs 
Mouse immunisation and generation of mAbs were performed as described previously 
[24]. Briefly, NMRI mice (Harlan) were immunised three times subcutaneously with 
25 µg of recombinant PfRH240 (rPfRH240) per mouse adjuvanted with the Sigma 
Adjuvant System® (SAS, Sigma Aldrich). The mouse selected for cell fusion received 
an additional intravenous booster injection with 25 µg rPfRH240 in PBS. Myeloma cells 
(PAI) were mixed 1:5 with spleen cells in Iscove’s Modified Dulbecco’s Medium (IMDM, 
Sigma Aldrich) to seed about 0.2 million cells per well of ten 96-well culture plates. Five 
PfRH2-specific IgG antibody containing wells were identified by ELISA. 
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ELISA 
Maxisorp™ microtitre plates (Nunc, Thermo Scientific) were coated overnight (ON) at 
4 °C with 50 µL of a 4 µg/mL solution of rPfRH240. Wells were then blocked with 5% 
skim milk powder in PBS before applying serial dilutions of mouse serum or purified 
mAbs in PBS. An alkaline phosphatase-conjugated goat anti-mouse IgG (γ-chain 
specific) antibody (Sigma-Aldrich) was added for detection of bound IgG. Hundred 
µl/well of 1 mg/mL p-Nitrophenyl phosphate (pNPP, Sigma Aldrich) in substrate buffer 
were finally added and the optical density (OD) of the reaction product was recorded at 
405 nm. 
Isotypes of anti-PfRH2 mAbs were determined by detecting mAbs bound to 
rPfRH240-coated plates with alkaline phosphatase-conjugated antibodies specific for 
mouse IgG1, IgG2a, IgG2b or IgG3 (Southern Biotech). 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting 
Parasite lysates were prepared by saponin lysis of P. falciparum 3D7-infected 
erythrocytes as described elsewhere [20]. Briefly, percoll-synchronised parasite cultures 
were pelleted and erythrocytes lysed in 20-30 volumes of 0.06% (w/v) saponin in PBS 
for 20 min on ice. Parasites were washed once with PBS and the pellet dissolved in 3-5 
volumes of PBS.  
Hundred µL rPfRH240 (0.5 µg/gel) or parasite lysate was mixed equally with sample 
buffer (Laemmli buffer, Invitrogen) and heated for 15 min at 70 °C before loading on 
4-12% Bis-Tris gels (Life technologies). SeeBlue® pre-stained protein standard 
(Invitrogen) was used as a molecular weight marker. Following gel electrophoresis, 
proteins were transferred electrophoretically to nitrocellulose membranes. Blots were 
blocked with 3% milk powder in PBS containing 0.05% Tween-20, cut into strips and 
then incubated with 500 µL mouse serum (1:100) or purified mAbs (10, 1, 0.1 µg/mL). 
The strips were washed with 0.5% milk, 0.05% Tween in PBS, incubated with alkaline 
phosphatase-conjugated goat anti-mouse IgG heavy-chain antibodies (Sigma Aldrich) 
and afterwards treated with ECL Western blotting detection reagent (ECL Western 
Blotting Substrate, Pierce) to visualise bands. 
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Immunofluorescence assay (IFA) 
For immunofluorescence microscopy, parasite cultures were pelleted and diluted 1:5 in 
PBS to prepare smears. Slides were fixed in ice cold 60% methanol and 40% acetone 
for 2 min and blocked with 3% BSA in PBS. Fifty µL of 1:100 diluted mouse serum and 
10 µg/mL mAbs diluted in blocking buffer were added and incubated for one hour. 
Wells, painted on the slide with an oil-based water repellent pen, were washed five 
times with blocking buffer before 50 µL of detection antibody was added for an 
additional hour. Alexa 488-labeled goat anti-mouse IgG (H+L) antibodies (Invitrogen) 
were used to detect bound anti-PfRH2 mAbs or mouse serum antibodies and a directly 
Alexa 488-labeled mouse anti-RAP-1 5-2 mAb was used to stain the RAP-1 antigen 
[25]. Blocking buffer alone served as negative control. Finally, wells were washed five 
times, mounted with ProLong® Gold antifade reagent containing 4',6-diamidino-2-
phenylindole (DAPI, Invitrogen) and covered with a coverslip. Antibody binding and 
DNA staining were assessed by fluorescence microscopy (magnification X63). 
 
In vitro growth inhibition assays 
In vitro growth inhibition assays were performed as described elsewhere [26]. Briefly, 
50 µL P. falciparum 3D7 cultures were set up in triplicate in 96-well culture plates with 
50 µL purified anti-PfRH2 mAbs in final concentrations of 500, 250 and 125 µg/mL for 
96 hours (two cycles of erythrocyte invasion). For combination tests, 250 or 125 µg/mL 
finally concentrated anti-PfRH2 mAbs were mixed with same concentrations of the 
parasite growth-inhibitory anti-CyRPA mAb c12 [27] in 50 µL PBS. Hydroethidine™ 
(0.15 µg/mL) was used to stain viable parasites and the assay was analysed in a 
FACScan flow cytometer (Becton Dickinson, San Jose, CA) using the CellQuest 
software. For each sample a total of 30,000 cells were analysed and the percent growth 
inhibition calculated from the mean parasitemia of triplicate test and control wells as 
follows: percent inhibition = (control-test)/(control/100). Anti-CyRPA mAb c12 and an 
isotype-matched control (anti-mycolactone) mAb JD5.2 were included as positive and 
negative control, respectively. 
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In vivo growth inhibition assays 
MAbs were tested in the P. falciparum SCID murine model [28] employing 
non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes 
essentially as described [27, 28]. Human blood (0.75 mL) was administered daily by the 
intravenous (i.v.) or intraperitoneal route. Three mice per group received a single dose 
of 0.5 or 2.5 mg anti-CyRPA mAb c12 and one mouse a single dose of 2.5 mg 
anti-PfRH2 mAb AS2 by i.v. injection one day before infection with 3 x 107 parasitised 
erythrocytes. The control group received the same volume of PBS. Parasitemia was 
monitored daily by flow cytometry over six days (day four to nine after mAb injection).  
 
Statistical analysis 
All data were obtained from experiments performed in duplicate (at a minimum). In each 
experiment antigen-free controls (PBS instead of sample) were included to determine 
the cut-off. Mean value, standard deviation and percent growth inhibition was calculated 
in Microsoft Excel. Figure assembly, data transformation and non-linear regression 
(sigmoidal curve, dose-response variable slope) were done with GraphPad Prism and 
Adobe Photoshop. 
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 Results 5.4
Generation of PfRH2-specific mAbs 
All mice, immunised three times with 25 µg of adjuvanted rPfRH240, developed high 
anti-PfRH2 IgG titres in ELISA (Fig. 1A). In Western blotting analysis with rPfRH240, 
serum antibodies stained, as expected, a band with a molecular mass of about 40kDa 
(Fig. 1B). When tested with P. falciparum 3D7 schizont lysate, the immune sera stained 
predominantly a 80kDa band (Fig. 1B), one of the fragments (80, 140, 220kDa [14]) 
expected for the endogenous PfRH2. In immunofluorescence microscopy with fixed in 
vitro cultivated schizonts, a dotted staining was observed with all sera (Fig. 1C) 
consistent with the localisation of the endogenous protein in the parasite rhoptries [11–
13, 17].  
Five hybridoma cell clones (AS1-AS5) producing anti-PfRH2 mAbs of the IgG1(λ) 
isotype were generated by conventional B cell hybridoma technology with spleen cells 
of one of the immunised mice and screening with rPfRH240 coated ELISA plates.  
 
Characterisation of PfRH2-specific mAbs 
All five generated mAbs recognised rPfRH240 both in ELISA (Fig. 2A) and in Western 
blotting analysis with comparable efficiency. On fixed parasites, they all yielded the 
expected dotted staining pattern (Fig. 2C). Anti-RAP-1 mAb [25] was included as 
positive control staining of the rhoptry bulb of P. falciparum (Fig. 2C). However, in 
Western blot analysis with schizont lysate, staining was only observed with mAb AS2, 
showing specific signals at 80 and 220kDa (Fig. 2B).  
 
Performance of anti-PfRH2 mAbs in in vitro growth inhibition assays 
Even at a concentration as high as 500 µg/mL, none of the five mAbs generated 
showed any in vitro parasite growth inhibitory activity (Fig. 3A). Also in combination with 
the parasite growth inhibitory anti-CyRPA mAb c12 [27], anti-PfRH2 mAbs caused no 
significant enhancement of the inhibitory activity (Fig. 3B).  
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Performance of anti-PfRH2 mAbs in an in vivo growth inhibition assay 
The Western blotting positive mAb AS2 was selected for testing in the P. falciparum 
mouse infection model, employing non-myelodepleted NOD-scid IL2Rγnull mice 
engrafted with human erythrocytes [28]. In the PBS control group parasitemia reached 
19.4 ± 0.8% by the end of the experiment at day nine (Fig. 4). Anti-PfRH2 mAb AS2 
showed no parasite inhibitory effect in vivo. In contrast, parasite growth in the presence 
of the anti-CyRPA control mAb c12 was inhibited in a dose dependent manner as 
expected with a parasitemia at day nine of 2.3 ± 0.6% (2.5 mg) and 10.1 ± 2.3% 
(0.5 mg).  
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 Discussion 5.5
PfRH2 is a protein located in rhoptries of blood stage merozoites [2, 13, 29] that is one 
of the parasite ligands translocated to the moving junctions and the parasite surface 
during invasion to bind erythrocytes through sialic acid independent receptors [13, 18, 
19]. Our study was conducted to evaluate the potential of antibodies raised against 
rPfRH240 to inhibit erythrocyte invasion. 
 
We generated a set of five mAbs specific for the 40kDa receptor-binding domain of 
PfRH2 that showed cross-reactivity with PfRH2, associated with the rhoptries of 
schizont stage parasites. Although specific binding of the mAbs to their target structure 
could thus be demonstrated, they showed no biological activity in an in vitro growth 
inhibition assay. Furthermore, none of the five anti-PfRH2 mAbs enhanced the growth 
inhibitory activity of the anti-CyRPA mAb c12 [27]. The anti-PfRH2 mAb AS2, tested in 
addition in the in vivo P. falciparum SCID-murine model [28], showed no inhibitory effect 
on parasite growth. In contrast, a parasite in vitro growth inhibitory activity has been 
described for polyclonal anti-PfRH2 antibodies [2, 8, 11–16]; in two of these studies 
rabbits had been immunised with the 40kDa receptor-binding domain of PfRH2 
(PfRH240) also used here. Our results show, that binding of antibodies to this 
receptor-binding domain does not inevitably lead to inhibition of erythrocyte invasion by 
merozoites. Possibly, binding of antibodies to several epitopes of PfRH2 is required to 
achieve the relatively limited inhibitory activity (25% [14] and about 30% [15]) observed 
at a high end final concentration (5 mg/mL) of polyclonal anti-PfRH240 rabbit IgG. 
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 Conclusion 5.6
PfRH2 is regarded as a potential malaria blood stage candidate vaccine antigen located 
in the apical organelles of merozoites and interacting with receptors on the surface of 
erythrocytes. While several studies have shown that polyclonal anti-PfRH2 antibodies 
can partly inhibit merozoite invasion, in vitro we have not found such an activity for 
parasite-binding mAbs generated against the PfRH2 receptor-binding domain.  
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 Figures 5.8
 
 
Figure 1. Immunogenicity of rPfRH240 in mice 
Serum samples, taken before immunisation (Pre), after the first (1. Imm), the second (2. Imm) and the 
third immunisation (3. Imm) of mice with adjuvanted rPfRH240 , were tested for the induction of anti-PfRH2 
IgG antibodies. (A) Titration (1:3 dilution steps) of sera tested in ELISA on plates coated with rPfRH240. 
(B) Western blot profiles obtained with 1:100 diluted mouse sera after SDS-PAGE separation of 
P. falciparum strain 3D7 schizont lysate or rPfRH240. (C) Staining of methanol/acetone fixated schizont 
parasites with 1:100 diluted mouse serum (green) by immunofluorescence microscopy. Nuclei were 
stained with DAPI (blue). Merged pictures of both stainings are shown in the right panel. Scale bars 
represent 5 µm. Original magnification X63. 
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Figure 2. Antigen-binding activities of anti-PfRH2 mAbs 
(A) Titration of mAbs (1:4 dilution steps starting from a concentration of 125 µg/mL) in ELISA using plates 
coated with rPfRH240. (B) Western blot staining pattern obtained with mAb AS2 (concentration: 
1: 10 µg/mL, 2: 1 µg/mL and 3: 0.1 µg/mL) on P. falciparum strain 3D7 schizont lysate containing PfRH2 
derived proteins of 80, 140, 220kDa. (C) Immunofluorescence staining of methanol/acetone fixed schizont 
parasites with mAb AS2 (concentration: 10 µg/mL). Nuclei were stained with DAPI (blue). Anti-RAP-1 
mAb 5-2 and PBS were included as controls. The right panel shows merged pictures. Scale bars 
represent 5 µm. Original magnification X63. 
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Figure 3. In vitro growth inhibitory effect of anti-PfRH2 mAbs 
(A) Single mAbs (500, 250 and 125 µg/mL) and (B) mAb combinantions of 250, 125 µg/mL anti-PfRH2 
mAbs and 250, 125 µg/mL anti-CyRPA mAbs, respectively, were incubated with synchronised 
P. falciparum 3D7 parasites for 96 hours to access their effect on merozoite invasion. Assays were 
performed in 96-well culture plates with parasite cultures adjusted to a final haematocrit and parasitemia 
of 0.5%. The parasite growth inhibitory anti-CyRPA mAb c12 and the unrelated isotype-matched 
anti-mycolactone mAbs JD5.2 were included as positive and negative control, respectively. Parasite 
growth inhibition was calculated against the parasitemia of PBS controls and expressed as percent 
growth inhibition. MAbs were tested in triplicate with single bars representing the mean value. Error bars 
indicate the SD. 
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Figure 4. In vivo growth inhibitory effect of anti-PfRH2 mAbs 
NOD-scid IL2Rγ
null 
mice were infected with P. falciparum 3D7 one day after receiving 0.5 or 2.5 mg 
anti-CyRPA mAb c12 or 2.5 mg anti-PfRH2 mAb AS2 by i.v. injection. Parasitemia was monitored over six 
days. The mean parasitemia in human erythrocytes in the peripheral blood of three mice per group is 
depicted with error bars indicating the SD. Only one mouse received anti-PfRH2 mAb AS2. PBS served 
as negative control, the anti-CyRPA mAb c12 as positive control. 
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 General Discussion and Conclusions 6.
 Monoclonal antibodies as multifunctional tools 6.1
Since the discovery of the hybridoma technology in 1975 by Georges J. F. Köhler and 
César Milstein, monoclonal antibodies (mAbs) have been used for various applications 
including research, diagnostics and therapy [1]. One current focus is the clinical use of 
mAbs as immune suppressor after transplantations (e.g. Muromonab-CD3) as well as 
therapeutics to treat autoimmune diseases, cancer and other diseases such as allergic 
asthma or cardiovascular problems [2]. The use of mAbs against infectious diseases is 
yet uncommon with only two mAbs approved for the treatment of respiratory syncytial 
virus (Palivizumab) and Bacillus anthracis infections (Axibacumab) [3]. Although several 
mAbs for the treatment of different viral, bacterial and fungal infections are currently 
tested in clinical trials, none of them target parasitic diseases [4]. In addition to their 
therapeutic use, mAbs are suitable to determine HLA and tumour markers, pregnancy 
and blood groups as well as for the detection of pathogens and the diagnosis of 
diseases. Especially in the nuclear medicine, mAbs became an important diagnostic 
tool for various infectious and inflammatory diseases and cancer [3, 5]. Furthermore, 
mAbs are widely used in basic laboratory research for the identification, localisation, 
quantification and characterisation of target molecules by standard assays such as 
Western blotting, microscopy/ immunofluorescence microscopy, ELISA, flow cytometry, 
immunohistochemistry and immunoprecipitation [1, 6]. 
 
Within the framework of this thesis, we generated mAbs against surface antigens of 
Brucella species for implementation in new antigen detection tools as well as mAbs 
against the reticulocyte-binding homolog 2 (PfRH2) of Plasmodium falciparum to 
evaluate their potential to inhibit erythrocyte invasion as an important criterion for the 
qualification of the target antigen as vaccine component. 
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 A sensitive mAb-based Luminex assay for Brucella spp. detection 6.2
With the production of Brucella lipopolysaccharide (LPS)-specific mAbs we were able to 
develop an antigen detection assay for Brucella species (spp.). This assay has proven 
favourable for various applications due to three main features: 1) the detection of 
Brucella spp. was possible in complex samples such as milk, 2) four potential bio-threat 
agents including Brucella spp. could simultaneously be detected in a multiplex format 
and 3) with 2 x 102 to 8 x 104 bacteria per mL the test shows a high sensitivity for the 
detection of Brucella spp. (Article 1).  
 
Detection of Brucella spp. in natural outbreaks 
Natural outbreaks of human brucellosis related to the consumption of unpasteurised 
dairy products have been reported from several countries, especially due to 
Brucella melitensis contaminations of sheep and goat milk [7–9]. In livestock (cattle, 
sheep, goats and camel) it was reported that up to 80% of infected animals constantly 
shed Brucella spp. into the milk due to persisting bacteria in the mammary glands and 
lymph nodes [10]. Furthermore, studies showed that B. melitensis could be isolated 
from sheep more than three years after initial infection and that one cow, infected with 
B. abortus, even shed bacteria into the milk for up to nine years post infection [11]. Such 
a continuous contamination of milk with viable Brucella spp. poses a major threat for 
animals and humans. In order to screen dairy livestock for Brucella infections, milk 
would be an optimal sample, since it is cheap and easily obtained either from bulk tanks 
where the milk of all animals is collected, or from individual animals. Collecting milk 
samples can be achieved without invasive methods and testing can be performed 
regularly and followed up with individual blood testing in case of a positive test result on 
milk [12, 13].  
 
The here developed Luminex assay is a promising new tool for the implementation in 
milk testing if further studies confirm the performance of the assay on raw milk samples 
of infected animals. So far, the detection of B. melitensis with the Luminex assay was 
comparable between spiked PBS and milk samples and was not impaired by other milk 
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contents. These findings indicate, that B. melitensis, B. abortus and B. suis could be 
detectable in milk with the same limits of 2 x 102, 5 x 103 and 8 x 104 bacteria per mL, 
respectively, as observed in experimental tests with PBS (Article 1).  
 
To date, bacterial culture is the gold standard for brucellosis diagnosis, since it reflects 
the current infection state by identifying viable Brucella spp., but serological assays are 
frequently performed to save time [10, 12, 14]. Two serological assays are commonly 
applied for detecting Brucella antibodies in milk, the milk/ Brucella ring test (BRT) and 
the indirect milk ELISA (iELISA). The advantages of the BRT are its simple execution 
and the fact that it can be read by eye. Additionally, it takes only one hour or, for 
increased sensitivity, overnight. The BRT shows a sensitivity of 85-89% and a specificity 
of 95% [15–17]. Despite these advantages, the World Organisation for Animal Health 
(OIE) stated that the BRT is not effective for detecting B. melitensis in milk [18]. In 
comparison, the iELISA assay, using ‘smooth’ B. melitensis LPS as coating antigen, 
revealed a sensitivity of 100% for B. abortus (23 out of 23) and 97% for B. melitensis 
(30 out of 31) in testing milk from infected cattle when compared to bacterial culture 
[19]. Several tests (ID Screen® Brucellosis Milk Indirect, SVANOVIR®Brucella-Ab I-
ELISA) are also commercially available but mainly for testing bovine milk [20, 21]. Both 
serological assays are simple, portable, sensitive and commercial assays enable 
standardised procedures. However, since the diagnosis relies on antibodies it rather 
reflects exposure than active disease. Also, antibodies elicited by vaccination or 
induced by bacteria sharing similar LPS, lead to false positive test results [14, 22].  
Furthermore, several molecular diagnostic methods have been evaluating milk to detect 
Brucella DNA. A study using an omp2-based PCR assay identified 65% of B. melitensis 
infected goats without cross-reactivities with closely related bacteria or Y. enterocolitica 
O3, O9, V. cholera O1 and E. coli. Furthermore, as few as ten Brucella bacteria 
(B. melitensis and B. abortus) could be detected in 1 mL of spiked milk [23]. A PCR 
assay using the 16S rRNA sequence of B. abortus had a detection limit of 170 
B. abortus cfu/mL and 1,700 B. melitensis cfu/mL in spiked milk samples. Direct 
comparison of the PCR assay and a B. melitensis LPS-based iELISA revealed 
sensitivities of 87.5% and 98.2%, respectively, compared to culture positivity of milk 
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samples from infected cows. Polymerase inhibitors in the milk are thought to interfere 
with the PCR [19]. A bcsp31-based multiplex PCR detected as few as 800-2,000 
B. abortus cfu/mL in spiked milk samples. Sensitivities were 85% with PCR and 75% 
with the BRT when milk was tested from B. abortus infected cows. On pooled bulk milk, 
PCR only identified four out of six samples (67%) correctly [24]. A study using an 
IS711-based PCR assay revealed a detection limit of 100 B. abortus cfu/mL and 1,000 
B. melitensis cfu/mL [25]. Molecular methods are complex and performed primarily in 
reference laboratories. Overall, sensitivities were comparable to serological assays 
available for milk testing. Newer approaches to detect Brucella spp. in milk such as the 
loop-mediated isothermal amplification (LAMP) assay are currently being developed. 
This assay was used to amplify DNA of several Brucella spp. in a single tube and 
Brucella spp. could be specifically detected in milk samples of infected animals [26]. 
Furthermore, micro-Raman spectroscopy was evaluated to identify Brucella spp. in 
spiked milk samples and sensitivities between 93.6 and 100% were observed for this 
technique [27]. 
 
All serological assays and molecular methods described here have certain advantages 
and disadvantages, need standardisations, improved sample preparation or further 
evaluation. The Luminex assay developed during the scope of this thesis proofed to 
have B. melitensis and B. abortus detection limits comparable with those of PCR-based 
methods. Furthermore, the assay is able to detect B. suis, is not negatively influenced 
by complex samples and can detect intact bacteria present in acute brucellosis 
infections. Despite these promising advantages, the Luminex assay is most likely too 
complex for testing milk samples on-site since it requires expensive machinery and 
trained personnel which makes the assay more suitable for applications in reference 
laboratories. Although lower sensitivities were reached with the corresponding capture 
ELISA (Article 1), it might still be possible to detect bacteria in milk. Additionally, ELISA 
applications are easier to perform and therefore more suitable for the implementation in 
decentralised control activities. Overall, the testing of individual and bulk milk samples is 
a suitable approach to detect infections in animals and the combination of several test 
methods might strengthen the diagnostic power. 
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Detection of bio threat agents including Brucella spp. in bioterrorism attacks 
Beside the application of the Luminex assay for detecting natural infections in livestock, 
the assay could also be implemented for the detection of bio threat agents in case of a 
bioterrorism attack. A possible scenario could be the contamination of the food chain. 
Since Brucella spp. can be killed by pasteurisation at 72-75 °C for 15 to 30 seconds 
[28], milk or other milk products would have to be contaminated after such procedures 
or during storage. The survival time of Brucella spp. in milk products is 87 days in UHT 
milk at 20 °C, up to four days in raw unpasteurised milk at 5 °C and less than a week in 
yogurt at 5 °C [28]. In areas where pasteurisation is not at all or insufficiently applied, 
infection of dairy livestock might lead to Brucella contaminations of milk products. Since 
the Luminex assay proved able to detect Brucella spp. in milk samples, the assay could 
also be applicable for testing other milk products. Appropriate preparation methods to 
homogenise or dissolve the sample in buffer have to be developed.  
 
Another possible infection scenario concerns the distribution of Brucella spp. via 
aerosols, with ten bacteria sufficient for the establishment of an infection [10, 12]. Such 
an aerosol distribution could also lead to a contamination of the environment since 
Brucella spp. are quite robust with survival times of 4 to 66 days in soil and 1 to >57 
days in open water [12]. In a potential bio threat situation, performing bacterial cultures 
is of great importance since this is the only method to investigate whether bacteria are 
still viable [12]. However, cultivation takes time and fast detection is required to access 
the dimensions and to implement appropriate measures and decontamination 
procedures [29]. Apart from this, multiplex assays are able to simultaneously test for 
different bio threat agents next to Brucella spp. as shown by different study groups [30–
32]: i) A multiplex PCR-based reverse line blot hybridisation assay (mPCR/RLB) was 
developed and simultaneously detected Bacillus anthracis, Yersinia pestis, B. melitensis 
and Burkholderia pseudomallei through hybridisation of species-specific biotin-labelled 
PCR products to membrane-bound probes [30]. In two other studies, the Luminex 
technology was used to detect amplified multiplex PCR products specific to ii) 
B. anthracis, Y. pestis, Francisella tularensis and B. melitensis [31] or iii) B. anthracis, 
Y. pestis, F. tularensis, Brucella spp. and B. pseudomallei [32] through hybridisation 
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with fluorescent-bead-labelled probes. All multiplex assays mentioned here were 
species-specific without cross-reactivities or interferences of different primer or target 
DNA samples. Detection limits of 0.3 pg (i), 0.1 pg (ii) and 22.5 pg (iii) were observed for 
Brucella template DNA with 1 pg corresponding to 200 bacteria.  
The developed Luminex assay is also capable of detecting four bio threat agents 
simultaneously. Since the detection of all four bacteria, Brucella spp., B. anthracis, 
F. tularensis and Y. pestis could be performed in a single sample without interferences 
or cross-reactivities, the assay represents a powerful tool for a simultaneous and high 
throughput detection of these organisms, especially if the source of the biological threat 
is unknown. The shown ability to detect all four bio threat agents in complex samples 
such as milk hints towards the probable applicability of the test for the detection of 
bacteria in environmental samples including soil or water. We could likewise show that 
inactivation methods such as gamma-irradiation, formalin inactivation or heat treatment 
did not affect the specific binding of the monoclonal antibodies to the Brucella surface 
(Article 1). Hence, the inactivation of a sample prior to testing would reduce the risk of 
accidental infection and therefore simplify further test procedures without interference 
with the antibody-antigen binding.  
 
Results of immunological assays such as the Luminex assay should be reconfirmed by 
PCR-based methods since cross-reactivities, mainly due to the structural similarities 
between O-antigens, are reported [14]. For the Luminex assay this applies for the 
Y. enterocolitica O9 O-antigen (Article 1). As mentioned before, several PCR assays 
are valid for detecting Brucella DNA in milk which could be applied for the detection of 
Brucella spp.. In addition, further conventional and real-time PCR assays are available 
[15]. However multiplex PCR-based approaches which target several bio threat agents 
[30–32] might be more suitable for this venture, especially if the biological threat agent 
is unknown and the possibility of an attack with multiple agents exists. PCR assays 
such as the ‘Bruceladder’ multiplex PCR [11] are able to differentiate all Brucella spp., 
including vaccine strains, to the species level within the same reaction. This 
species-level distinction is of great importance since not all Brucella spp. pose the same 
threat to human and animal hosts [14, 33, 34]. A combination of bacterial cultures, 
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sensitive antigen detection assays (Luminex assay) and appropriate PCR-based 
methods could allow fast and specific identification of biological threats for a detailed 
risk assessment and implementation of appropriate procedures. 
 
The Luminex assay as potential diagnostic tool 
Currently, the diagnosis of human and animal brucellosis is mainly based on cultivation 
and isolation of the causative organism supported by different serological diagnostic 
assays [10, 12, 14, 22, 35]. 
Although no clinical samples have been tested so far, the Luminex assay might enable 
the detection of intact bacteria or LPS present in blood, serum, organs/ tissue or body 
fluids of infected humans and animals. Especially, since low detection limits of 2 x 102, 
5 x 103 and 8 x 104 bacteria per mL for B. melitensis, B. abortus and B. suis, 
respectively, have been observed (Article 1). While antigen detection would be a strong 
indication for an ongoing infection, serological assays rather provide a retrospective 
picture of disease exposure. Recently, a similar approach was pursued using a 
mAb-based capture ELISA which is able to detect ‘smooth’ LPS in i) serum samples 
spiked with B. melitensis LPS, ii) serum of mice challenged with B. melitensis cells and 
iii) serum of humans with blood cultures positive for B. melitensis. The capture ELISA 
has proven to be a feasible tool for Brucella LPS detection in clinical samples [36]. The 
Luminex assay showed fewer cross-reactivities than serological assays [14, 22], which 
in addition to cross-reactivity with Y. enterocolitica O9 also seen with the Luminex 
assay, show also false-positive reactions with other similar O-antigens of 
Vibrio cholera O1 and Escherichia coli O157 and with Ochrobactrum anthropi, the 
closest relative of Brucella spp.. Furthermore, apart from B. canis and B. ovis, 
expressing a ‘rough’ LPS, all other classical Brucella spp., B. melitensis (biovar 1-3), 
B. abortus (1,3), B. suis (1,2) and B. neotomae can be detected by the Luminex assay, 
independently of the biovar. In addition, test results can be obtained within one day, 
saving time compared to bacterial culture and since the assay is performed in 96-well 
plates, a large number of samples can be tested in parallel.  
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 Immunodominant Brucella protein antigens  6.3
For ‘smooth’ Brucella spp. it is known that the LPS predominantly mediates the antibody 
response upon infection and therefore almost all serological assays are based on 
‘smooth’ LPS as target antigen [22, 37, 38]. However, analyses of sera from naturally or 
experimentally infected animals and humans with confirmed brucellosis revealed that 
Brucella protein antigens also stimulate the immune system. Identified antigens include 
enzymes (superoxide dismutase, transaldolase), heat shock proteins (chaperone DnaK, 
GroEL), binding proteins (ABC amino acid transporter periplasmic binding protein), 
ribosomal proteins, proteins for energy production and reduction/oxidation reactions 
(ATP synthase, fumarate reductase) and membrane associated proteins (OMP2b, 
OMP16, OMP31b, OMP25, Bp26) [39–43]. Such immunodominant proteins are of great 
interest for various applications such as serological assays, antigen detection systems, 
vaccine development and epidemiological studies. Furthermore, since ‘smooth’ LPS is 
inadequate for testing for exposure to ‘rough’ Brucella spp. such as B. canis and B. ovis 
[22, 35], protein antigen-based tests might offer better prospects.  
 
Our Western blotting analyses on Brucella lysate identified both LPS and 
protein-specific antibodies in the serum of naturally infected cattle and mice immunised 
with whole Brucella cells (Article 2). For antigen characterisation and applications in 
antigen detection assays, monoclonal antibodies were produced from the mice 
immunised with whole Brucella bacteria. However, only LPS-specific mAbs were 
obtained, although comparable studies on Mycobacterium ulcerans and 
Neisseria meningitidis in our laboratory had shown that cell surface protein-specific 
mAbs can be produced by mouse immunisation with and hybridoma screening on 
bacterial cells [44]. However, our mass spectrometry analysis, performed with Brucella 
proteins reactive with mouse immune serum, revealed no Brucella surface-exposed 
proteins. Since Brucella spp. are intracellular pathogens, immune responses against 
almost any antigen might be elicited by natural infection upon processing of the bacteria 
by macrophages [45]. While for antigen detection assays surface exposed antigens are 
required to recognise whole cells, the identified non-surface exposed immunodominant 
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proteins of Brucella spp. might be suitable for serological testing. With proteins instead 
of ‘smooth’ LPS as target antigens it may be possible to develop serological tests that 
differentiate between vaccination, exposure to different Brucella spp. and exposure to 
other gram negative bacteria with cross-reactive O-antigens [14, 22]. To evaluate 
whether identified immunodominant proteins are suitable antigens for serological 
approaches, series of sera from exposed humans and animals need to be screened to 
select antigens with the best performance for particular hosts.  
 
Towards a safe and effective vaccine against human brucellosis different approaches 
are on the way. Subunit vaccines based on recombinant proteins or plasmid DNA are 
promising vaccine candidates since they are more safe than live-attenuated vaccines 
[46]. For potential inclusion into subunit vaccines several proteins have been tested 
alone or in combination with other antigens or delivery systems in mouse models for 
brucellosis [47]. Some of these antigens such as OMP16 [48, 49], OMP31 [50–53], Cu-
Zn superoxide dismutase [54–56] and Bp26 [57], formulated as protein or DNA vaccine, 
showed good protective efficacies similar to live attenuated animal vaccines [47]. Since 
these protective protein antigens were identified by serum analyses for 
immunodominant antigens [39–43], testing of sera from humans and animals infected 
with Brucella spp. seems to be a suitable and powerful tool to identify new proteins with 
potential for subunit vaccines. While some of the vaccine candidates showed promising 
results in mouse models, none of them has been tested in clinical trials. 
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 New malaria blood stage candidate vaccines 6.4
Currently, malaria is threatening almost half of the world’s population with recent 
estimates of 200 million infected people and more than half a million deaths per year. 
Within the Plasmodium species, P. falciparum is the most virulent responsible for 98% 
of malaria-related deaths, primarily among children below the age of five in sub-
Saharan Africa [58, 59]. Upon an infectious mosquito bite parasites enter the human 
body where they first invade hepatocytes to undergo initial development steps before 
they enter the blood stream to invade and replicate in erythrocytes. Clinical symptoms 
of malaria and severe disease are directly linked to the erythrocytic phase due to the 
release of parasite-derived toxic substances into the blood upon rupture of the infected 
erythrocyte, the release of cytokines by the host and sequestration of the infected 
erythrocytes [60, 61]. Although, the development and replication of P. falciparum 
parasites is primarily intracellular, i) sporozoites entering the human body through an 
infectious bite and ii) merozoites released from infected hepatocytes and erythrocytes 
are exposed to the extracellular environment and to the humoral immune system. To 
allow invasion, these extracellular forms need close cell-cell interactions with host cells 
which is mediated by surface molecules and molecules secreted from apical organelles 
of the parasite. Such proteins are potential targets for protective antibodies and 
therefore candidate antigens for the development of a blood stage vaccine [60]. 
Evidences that humans can be vaccinated against malaria were obtained by individuals 
living in endemic areas with frequent exposure to malaria who became first resistant to 
severe malaria and later on to clinical disease [62]. In addition, the fact that 
immunoglobulin transferred from semi-immune adults to P. falciparum-infected children 
reduced parasitaemia, showed that antibodies are relevant for immune protection 
against P. falciparum blood stages [63]. Therefore, attempts are made to develop a 
blood stage component for a malaria vaccine that elicits antibodies which either block 
erythrocyte invasion or inhibit subsequent replication of the parasites [64]. 
 
Currently, vaccine development against blood stage parasites relies on a handful of 
merozoite antigens including AMA1, EBA-175, GLURP, MSP1, MSP2, MSP3 and 
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SERA5. Most of them are evaluated in phase I trials to assess safety and 
immunogenicity aspects [65–77]. Phase II trials with the leading candidate antigens 
AMA1 and MSP1 failed to effectively protect from clinical malaria [78–81]. Also a 
vaccine combining MSP1, MSP2 and the ring-infected erythrocyte surface antigen 
(combination B) did not effectively protect children from clinical malaria episodes [82]. 
However, an AMA1 and CSP-based DNA vaccine, boosted with adenovirus vectors, 
induced sterile protection in 27% of naïve adults when challenged with bites of infected 
mosquitoes due to cell-mediated immunity to AMA1 and CSP [83]. Furthermore, it was 
reported that AMA1 and CSP-based peptidomimetics, formulated in virosomes, reduced 
the rate of clinical malaria episodes in vaccinated children by 50% [84]. These 
multistage candidate vaccines combine an anti-infection component (CSP) against 
sporozoites and an anti-invasion as well as an anti-disease component (AMA1) against 
merozoites [85]. In comparison, RTS,S/AS01, a pre-erythrocytic vaccine based on CSP 
and the leading candidate in P. falciparum malaria vaccine development, efficiently 
protects 36% of young children and 26% of infants from clinical malaria in sub-Saharan 
Africa [86, 87]. 
 
To contribute to the development of new blood stage candidate vaccines, we evaluated 
the P. falciparum reticulocyte-binding homolog 2 (PfRH2) in functional in vitro assays 
and in an in vivo mouse model (Article 3). PfRH2 is a member of the 
reticulocyte-binding homolog (PfRH) family including PfRH1-5, expressed in schizonts 
and merozoites where it is located in the rhoptry neck of apical organelles interacting 
with receptors on the surface of erythrocytes. Previous studies revealed that serum 
antibodies induced upon immunisation of rabbits with different PfRH2 fragments were 
able to efficiently block erythrocyte invasion by P. falciparum merozoites in vitro [88–95]. 
To confirm these observations, we immunised mice with the 40kDa receptor-binding 
domain of PfRH2 and generated PfRH2-specific mAbs by B cell hybridoma technology. 
These mAbs cross-reacted with the endogenous PfRH2, produced by schizont stage 
parasites and showed a rhoptry-characteristic staining in immunofluorescence 
microscopy but failed to inhibit erythrocyte invasion by P. falciparum merozoites in vitro 
(Article 3). While binding of the produced mAbs to the receptor-binding domain of 
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PfRH2 was not enough to inhibit invasion, it is possible that different epitopes of PfRH2 
have to be targeted to achieve an invasion inhibitory effect.  
 
Functional in vitro assays such as the growth inhibition assay (GIA) are frequently used 
to assess the functionality of vaccine-induced antibodies, both in pre-clinical studies and 
in clinical trials by measuring antibody-dependent inhibition of parasite replication and 
erythrocyte invasion [96]. These assays offer a rapid and simple tool to evaluate new 
blood stage candidate vaccine antigens potentially involved in the invasion of or the 
replication in erythrocytes. However, concerns exist about the significance of such 
assays, especially regarding a future potential protective effect in humans against 
clinical malaria. Alternatively, the growth inhibitory effect of antibodies can be studied in 
vivo in nonhuman primates or rodent models such as SCID-mice engrafted with human 
erythrocytes. Recently, the P. falciparum NOD-scid IL2Rγnull mouse model, engrafted 
with human erythrocytes, was used to evaluate a new blood stage candidate vaccine 
antigen of P. falciparum, the cysteine-rich protective antigen (PfCyRPA) [97, 98]. It has 
recently been reported that a complex, which is essential for the invasion of 
erythrocytes by P. falciparum, is formed including PfCyRPA, the reticulocyte-binding 
homolog 5 (PfRH5) and the PfRH5-interacting protein (PfRipr) [99]. Furthermore, PfRH5 
is another promising blood stage candidate vaccine inducing inhibitory antibodies and 
capable of efficiently protecting Aotus monkeys against P. falciparum challenge [100–
104]. PfCyRPA-specific mAbs, which showed already strong parasite growth inhibitory 
activity in vitro, did also protect mice by passive immunisation. Parasite multiplication in 
this SCID-mouse model is very reproducible and a determination of the concentration of 
antibodies, required for parasite growth inhibition, is possible by analysing the 
dose-dependency of the inhibitory activity (Article 3). As already indicated by the 
negative in vitro results, no parasite growth inhibitory activity was observed when 
PfRH2-specific mAbs where tested in the SCID-mouse model. Furthermore, the 
PfRH2-specific mAbs did not enhance the in vitro growth inhibitory effect of 
PfCyRPA-specific mAbs. 
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 Conclusions 6.5
In this thesis the generation of monoclonal antibodies against immunodominant Brucella 
cell surface antigens and the P. falciparum reticulocyte-binding homolog 2 (PfRH2) is 
described. The monoclonal antibodies were used for the development of a sensitive 
antigen detection assay specific for Brucella spp. and contributed to the evaluation of 
PfRH2 as potential new P. falciparum blood stage candidate vaccine antigen.  
Major findings are: 
 
1. Serum of mice immunised with whole Brucella cells and cattle naturally infected 
with Brucella spp. were used to identify immunodominant Brucella antigens. 
Western blot analyses on Brucella lysate revealed the generation of serum 
antibodies against both LPS and a range of Brucella proteins. However, mass 
spectrometry analyses showed that none of the proteins reactive with the mouse 
immune sera was located on the bacterial cell surface and thus suitable as target 
for an antigen capture assay for the detection of Brucella cells. 
 
2. When spleen cells of mice immunised with whole Brucella cells were used for the 
generation of monoclonal antibodies (mAbs) by B cell hybridoma technology, 
exclusively mAbs specific for the O-antigen of lipopolysaccharide (LPS) were 
obtained. Attempts to produce Brucella protein-specific mAbs by this immunisation 
approach and screening by whole cell ELISA were not successful. 
 
3. For the development of an antigen capture assay detecting Brucella spp. bacteria, 
two LPS-specific mAbs were selected. While mAb 1 was coupled to magnetic 
beads to capture the antigen, a biotinylated mAb 2 was used for detection. 
Implemented in the Luminex xMAP technology, the mAbs specifically detected 
Brucella spp. expressing ‘smooth’ LPS with high sensitivities. 
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4. The developed Luminex assay was integrated in a multiplex format and allowed for 
the simultaneous and specific detection of the four bio threat agents Brucella spp. 
Bacillus anthracis, Francisella tularensis and Yersinia pestis in complex samples. 
 
5. Mice were immunised with the 40kDa receptor-binding domain of the P. falciparum 
reticulocyte-binding homolog 2 (PfRH2) and PfRH2-specific mAbs were generated 
by B cell hybridoma technology. All mAbs recognised the erythrocyte invasion 
ligand PfRH2, produced by schizont stage parasites, and showed a rhoptry-
characteristic staining in immunofluorescence microscopy. 
 
6. To access whether PfRH2-specific mAbs are able to inhibit erythrocyte invasion by 
P. falciparum merozoites, mAbs were tested in an in vitro growth inhibition assay. 
None of the PfRH2-specific mAbs showed any activity on its own and the parasite 
growth inhibitory activity of cysteine-rich protective antigen (PfCyRPA)-specific 
mAbs was not enhanced by PfRH2-specific mAbs. Furthermore, when tested in a 
P. falciparum experimental infection model based on NOD-scid IL2Rγnull mice 
engrafted with human erythrocytes, PfRH2-specific mAbs did not show parasite 
inhibitory activity. 
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